AU2008228714B2 - Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate - Google Patents

Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate Download PDF

Info

Publication number
AU2008228714B2
AU2008228714B2 AU2008228714A AU2008228714A AU2008228714B2 AU 2008228714 B2 AU2008228714 B2 AU 2008228714B2 AU 2008228714 A AU2008228714 A AU 2008228714A AU 2008228714 A AU2008228714 A AU 2008228714A AU 2008228714 B2 AU2008228714 B2 AU 2008228714B2
Authority
AU
Australia
Prior art keywords
amount
present
propylene glycol
weight
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008228714A
Other versions
AU2008228714A1 (en
Inventor
Dilbir S. Bindra
Mandar V. Dali
Prakash V. Parab
Jatin M. Patel
Li Tao
Ravindra W. Tejwani
Nipa Vatsaraj
Yongmei Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39671801&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2008228714(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2008228714A1 publication Critical patent/AU2008228714A1/en
Application granted granted Critical
Publication of AU2008228714B2 publication Critical patent/AU2008228714B2/en
Priority to AU2014201239A priority Critical patent/AU2014201239B2/en
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB Request for Assignment Assignors: BRISTOL-MYERS SQUIBB COMPANY
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include dapagliflozin propylene glycol hydrate is: Formula (Ia) or Formula (Ib) and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release. The formulations are used for the treatment of diabetes and related diseases.

Description

PHARMACEUTICAL FORMULATIONS CONTAINING AN SGLT2 INHIBITOR [0001] This application claims priority to U.S. Provisional Serial No. 60/896,286, filed on March 22, 2007. FIELD OF THE INVENTION [00021 The present invention provides an immediate release pharmaceutical formulation which includes a tablet or capsule formulation containing the sodium dependent glucose transporter (SGLT2) inhibitor dapagliflozin or its propylene glycol hydrate. BACKGROUND OF THE INVENTION 100031 At least 171 million people worldwide suffer from type II diabetes (NIDDM), which is characterized by hyperglycemia due to excessive hepatic glucose production and peripheral insulin resistance. Hyperglycemia is considered to be the major risk factor for the development of diabetic complications, and is likely to contribute directly to the impairment of insulin secretion seen in advanced NIDDM. Thus, consistent control of plasma glucose levels in NIDDM patients can offset the development of diabetic complications and beta cell failure seen in advanced disease. Plasma glucose is normally filtered in the kidney in the glomerulus and actively reabsorbed in the proximal tubule. SGLT2 appears to be the major transporter responsible for the reuptake of glucose at this site. A selective inhibitor of the sodium-dependent glucose transporter SGLT2 in the kidney is expected to normalize plasma glucose levels by enhancing the excretion of glu ose in the urine, thereby improving insulin sensitivity, and delaying the development of diabetic complications. 10004] The compound of the structure (I) IEt HO HO' /OH OH
-I-
or phannaceutically acceptable salts or solvates thereof (hereinafter dapagliflozin), an orally active SGLT2 inhibitor is disclosed in U.S. Patent No. 6,515,117 (the disclosure of which is incorporated herein by reference in its entirety). [0005] U.S. Application Serial No. 11/765,481 filed June 28, 2007, published as US 2008-0004336 Al discloses dapagliflozin in the forn of its (S)-propylene glycol ((S) PG) hydrate and its (R) -propylene glycol ((R)-PG) hydrate. The (S)-propylcnc glycol hydrate is referred to as form SC-3 and has the structure shown as (Ia). ORt HO 0 HO \CH 3 HO HO H6O OH OH C - Hs OHHy Ia (SC-3) [0006] The (R)-propylene glycol hydrate is referred to as form SD-3 and has the structure shown as (Ib). OEt C| \ HO .02 -H CH3 HO\\ /H H2OH" OH lb (SD-3) [00071 Methods for preparing the (S)-PG hydrate and the (R)-PG hydrate of dapagliflozin are provided in U.S. Application Serial No. 11/765,481 filed June 28, 2007, published as US 2008-0004336 Al (the disclosure of which is incorporated herein by reference in its entirety). BRIEF DESCRIPTION OF THE INVENTION 100081 Described herein are pharmaceutical formulations which can be in the form of a capsule formulation or a tablet formulation, for oral use, designed for -2immediate release, and include as the medicament dapagliflozin which has the structure (I) OEt C1 / \/ HO HO ~ O 1 H OH or a pharmaceutically acceptable salt, solvate, mixed solvate, or complex thereof (which is disclosed in U.S. Patent No. 6,515,117 herein incorporated by reference in its entirety) and a pharmaceutically acceptable carrier thereof Accordingly, in a first aspect the invention provides an immediate release pharmaceutical formulation in the form of a stock granulation for loading in capsules or forming tablets, or in the form of a tablet or capsule, the pharmaceutical formulation comprising: a) dapagliflozin propylene glycol hydrate having the formula OEt Cl / /\
H
2 0 HO 0\CH 3 HOU 1 0H OH OH present in an amount within the range of from about 0.1 to about 70% by weight of stock granulation or of tablet or capsule fill; b) one or more bulking agents present in an amount within the range of from about 1 to about 95% by weight of the stock granulation or of tablet or capsule fill; c) one or more binders present in an amount within the range of from about 0 to about 20% by weight of of the stock granulation or tablet or capsule fill; -3e) optionally, a glidant and/or anti-adherent present in an amount within the range of from about 0 to about 20% by weight of the stock granulation or of tablet or capsule fdl; and f) optionally, a lubricant present in an amount within the range of from about 0% to about 5% by weight of the stock granulation or of tablet or capsule fill. 100091 In the formulations of the invention, the dapagliflozin is in the form of its (S)-propyleno glycol ((S)-PG) hydrate (SC-3) which is shown as Compound (Ia) OEt / \l HO O HO \\"CH 3 HO HO HO " "'- H20 .
r HO1OH OH CH, OH (o Compound la the preparation for which is disclosed in U.S. Application Serial No. 11/765,481, filed June 28, 2007, U.S. Publication No. 2008-0004336 Al, and Provisional Application No. 60/817,118, filed June 28, 2006, the disclosures of both of which are incorporated herein by reference in their entireties. [0010] In one embodiment of the invention, the immediate release pharmaceutical formulation of the invention is in the form of a stock granulation (e.g., granules, beads, and/or beadlets), for loading in capsules or forming into tablets, comprising a) dapagliflozin propylene glycol hydrate; b) one or more bulking agents; c) optionally one or more binders; d) optionally one or more disintegrants; e) optionally one or more glidants and/or anti-adhcrents; and f) optionally one or more lubricants. 100111 In one embodiment, the stock granulation comprises dapagliflozin propylene glycol hydrate and one or more bulking agents. Suitable bulking agents -4include, for example, microcrystalline cellulose and/or lactose, as well as others provided herein and known in the art. In other embodiments, the stock granilation optionally comprises one or more of the following compounds: (1) one or more binders; (2) one or more disintegrants; (3) one or more glidants and/or anti adherents; and (4) one or more lubricants. Suitable binders include, for example, pregelatinized starch, as well as others provided herein and known in the art. Suitable disintegrants include, for example, sodium starch glycolate, crospovidone, and croscamellose sodium, as well as others provided herein and known in the art. Suitable glidants and/or anti-adherents include, for example, silicon dioxide and talc, as well as others provided herein and known in the art. Suitable lubricants include, for example, magnesium stearate, as well as others provided herein and known in the art. 100121 The stock granulation of the invention as described above, and capsules and tablets containing same, is prepared by mixing together dapagliflozin propylene glycol hydrate and one or more bulking agents, in any desired order, to form the stock granulation; and filling the capsules with or forming tablets from desired quantities of the stock granulation. In other embodiments, the stock granulation of the invention is prepared by mixing together dapagliflozin propylene glycol hydrate and one or more bulking agents; and optionally one or more of the following compounds: binder(s); disintegrant(s); glidant(s) and/or anti-adherent(s); and lubricant(s) in any desired order, to form the stock granulation and filling the capsules with or forming tablets from desired quantities of stock granulation. [0013] The tablets of the invention as described above are prepared by compressing the stock granulation into tablet form. In one embodiment, the tablets of the invention are prepared by compressing the stock granulation having one or more binder(s). In another embodiment, the tablets of the invention are prepared by compressing the stock granulation containing one or more anti-adherent(s) and/or glidant(s). In other embodiments, the tablets of the invention are prepared by compressing the stock granulation comprising one or more of the following compounds: (1) one or more binders; (2) one or more disintegrants; (3) one or more glidants and/or anti-adherents; and (4) one or more lubricants. -5- [0014] Optionally, the tablets and/or capsules of the invention can include an outer protective coating which comprises a coating polymer, such as, for example, polyvinyl alcohol (PVA), hydroxypropyl methyl cellulose, and hydroxypropyl cellulose, and/or a plasticizer(s) and optional colorant(s). Other optional components of the outer protective coating include anti-adherent(s) and/or glidant(o) and opacifying agont(3). [00151 The pharmaceutical dapagliflozin propylene glycol hydrate formulations of the invention including the stock granulation, capsules containing same, and tablets of the invention are useful in the treatment of mammals, such as humans, dogs, and cats, for diseases or disorders associated with SGLT2 activity. Thus, the invention provides pharmaceutical dapagliflozin propylene glycol hydrate formulations for use in the treatment of diseases or disorders associated with SGLT2 activity, for example, Type I and Type 11 diabetes; impaired glucose tolerance; insulin resistance; and diabetic complications, such as nephropathy, retinopathy, neuropathy and cataracts; hyperglycemia; hyperinsulinemia; hypercholesterolemia; dyslipidemia; elevated blood levels of free fatty acids or glycerol; hyperlipidemia; hypertriglyceridemia; obesity; wound healing; tissue ischemia; atherosclerosis; hypertension; and Syndrome X or Metabolic Syndrome. [0016] In one embodiment, the invention provides the pharmaceutical formulation of the invention for use in the treatment of type II diabetes. In another embodiment, the invention provides the pharmaceutical formulation of the invention for use in delaying the progression or onset of type II diabetes. [0017] The invention further provides a method for treating or delaying the progression or onset of diseases or disorders associated with SGLT2 activity comprising administering to a mamrpalian species in need of such treatment a therapeutically effective amount of a pharmaceutical formulation of the invention. In one embodiment, the invention provides a method for treating type II diabetes comprising administering to a mammalian species in need of such treatment a therapeutically effective amount of a pharmaceutical formulation of the invention. In one embodiment, the invention provides a method for delaying the progression or onset of type II diabetes comprising administering to a mammalian species in need -6of such treatment a therapeutically effective amount of a pharmaceutical formulation of the invention. [00181 Other therapeutic agent(s) suitable for combination with the formulations of the present invention include, but are not limited to, known therapeutic agents useful in the treatment of the aforementioned disorders associated with SGLT2 activity including: anti-diabetic agents; anti-hyperglycemic agents; hypolipidenic or lipid lowering agents; anti-obesity agents; anti-hypertensive agents and appetite suppressants. [0019] The invention further provides a method for treating or delaying the progression or onset of diseases or disorders associated with SGLT2 activity comprising administering to a mammalian species in need of such treatment a therapeutically effective amount of a pharmaceutical formulation of the invention and one or more of the following: an anti-diabetic agent(s), anti-hyperglycemic agent(s); hypolipidemic or lipid lowering agent(s); anti-obesity agent(s); anti hypertensive agent(s) and appetite suppressant(s). [0020] In one embodiment, the invention provides a method for treating type II diabetes comprising administering to a mammalian species in need of such treatment a therapeutically effective amount of a pharmaceutical formulation of the invention and one or more anti-diabetic agent(s). In one embodiment, the invention provides a method for delaying the progression or onset of type II diabetes comprising administering to a mammnalian species in need of such treatment a therapeutically effective amount of a pharmaceutical formulation of the invention and one or more anti-diabetic agent(s). In one embodiment, the invention provides a method for treating or delaying the progression or onset of type 11 diabetes comprising administering to a mammalian species in need of such treatment a therapeutically effective amount of a pharmaceutical formulation of the invention and one or more of the following: an anti-hyperglycemic agent(s); hypolipidemic or lipid lowering agent(s); anti-obesityagent(s); anti-hypertensive agent(s) and appetite suppressant(s). DETAILED DESCRIPTION OF THE INVENTION -7- [00211 The invention provides immediate release pharmaceutical formulations, which include, among others, tablet and capsule formulations, containing the sodium dependent glucose transporter (SGLT2) inhibitor dapagliflozin propylene glycol hydrate. 100221 As used herein, the term "dapagliflozin' is intended to mean the structure shown as structure I or Compound I. The term "dapagliflozin propylene glycol hydrate" is meant to refer to and encompass both dapagliflozin (S)-propylene glycol hydrate (structure Ia or Compound Ia). As used herein, the terms "pharmaceutical formulation", "pharmaceutical formulation of the invention", and "fonnulation" are meant to refer to formulations containing dapagliflozin propylene glycol hydrate. Likewise, the term "medicament" is meant in the present application to refer to dapagliflozin propylene glycol hydrate. 100231 As used herein, the terms "immediate release" and "immediate release pharmaceutical formulation" are intended to mean that the pharmaceutical formulations of the invention are not produced using excipients that interfere with absorption of the active pharmaceutical ingredient, for example, dapagliflozin propylene glycol hydrate, when administered to a mammal or human. [0024] The pharmaceutical formulation of the invention can be in the form of a capsule, tablet, bead, beadlet, granule or pill, all of the above being collectively referred to as pharmaceutical formulations, and contains medicament, namely dapagliflozin or dapagliflozin prupylene glycol hydrate. The medicament is dapagliflozin (S)-propylene glycol hydrate. In one embodiment of the invention, the immediate release pharmaceutical formulation of the invention is in the form of a stock granulation (e.g., granules, beads, and/or beadlets), for loading in capsules or fonning into tablets. [0025] The dapagliflozin propylene glyco I hydrate is in an amount within the range of from about 0.1% to about 70% by weight of the stock granulation and preferably in an amount within the range of from about 0.1% to about 30% by weight of the stock granulation. [00261 The pharmaceutical formulation of the invention can include pharmaceutical excipients as described herein to aid in the formation of a stock -8granulation suitable in the form of granules, beads, or beadlets for capsule loading and for tablets of the invention. In one embodiment, the pharmaceutical formulation is in the form of a capsule or tablet containing a stock granulation comprising a) dapagliflozin propylene glycol hydrate; b) at least one bulking agent or filler; c) optionally at least one binder; d) optionally at least one disintegrant; c) optionally at least one glidant and/or anti-adhcrcnt; and f) optionally at least one lubricant. [00271 In the described embodiments of the pharmaceutical fonnulations of the invention, the amounts of medicament (dapagliflozin propylene glycol hydrate) and each of the excipient(s) are expressed as a percentage weight of the total weight of the stock granulation, which is equivalent in measurement to the percentage weight of the total weight of the tablet or capsule fill. [0028] The dapagliflozin propylene glycol hydrate is in an amount within the range of from about 0.1% to about 70% by weight of the stock granulation. In one embodiment, the dapagliflozin propylene glycol hydrate is in an amount within the range of from about 0.1% to about 30% by weight of the stock granulation. [00291 The bulking agent or filler is present in an amount within the range of from about 1% to about 95% by weight of the stock granulation. In one embodiment, the bulking agent or filler is present in an amount within the rang of from about 10% to about 85% by weight of the stock granulation. 100301 The binder, if present, is present in an amount within the range of from about 0% to about 20% by weight of the stock granulation. In one embodiment, the binder, if present, is present in an amount within the range of from about 1% to about 10% by weight of the stock granulation. In another embodiment, the binder, if present, is present in an amount within the range of from about 2% to about 4% by weight of the stock granulation. 10031] The disintegrant, if present, is present in an amount within the range of from about 0% to about 20% by weight of the stock granulation. In one -9embodiment, the disintegrant, if present, is present in an amount within the range of from about 0.25% to about 10% by weight of the stock granulation. 100321 The glidant and/or anti-adherent, if present, is present in an amount within the range of from about 0% to about 20% by weight of the stock granulation. In one embodiment, the glidant and/or anti-adherent, if present, is present in an amount within the range of from about 1% to about 15% by weight of the stock granulation. [00331 The lubricant, if present, is present in an amount within the range of from about 0% to about 5% by weight of the stock granulation. In one embodiment, the lubricant, if present, is present in an amount within the range of from about 0.1% to about 5% by weight of the stock granulation. In another embodiment, the lubricant, if present, is present in an amount within the range of from about 0.2% to about 2% by weight of the stock granulation. [00341 In one embodiment, the pharmaceutical formulation is in the form of a capsule or tablet containing a stock granulation comprising a) dapagliflozin propylene glycol hydrate; b) at least one bulking agent or hiller; c) optionally at least one binder; d) optionally at least one disintegrant; e) optionally at least one glidant and/or anti-adherent; and f) optionally at least one lubricant. wherein a) the dapagliflozin propylene glycol hydrate is present in an amount within the range of from about 0.1% to about 70% by weight; b) the bulking agent or filler is present in an amount within the range of from about 1% to about 95% by weight; c) the binder, if present, is present in an amount within the range of from about 0% to about 20% by weight; d) the disintegrant, if present, is present in an amount within the range of from about 0% to about 20% by weight; 40 e) the glidant and/or anti-adherent, if present, is present in an amount within the range of from about 0% to about 20% by weight; and f) the lubricant, if present, is present in an amount within the range of from about 0% to about 5% by weight, all of the above % by weight being based on the weight of the stock granulation. 100351 In one embodiment, the pharmaceutical formulation is in the form of a capsule or tablet containing a stock granulation comprising a) dapagliflozin propylene glycol hydrate; b) at least one bulking agent or filler; c) optionally at least one binder; d) optionally at least one disintegrant; e) optionally at least one glidant and/or anti-adherent; and f) optionally at least one lubricant. wherein a) the dapagliflozin propylene glycol hydrate is present in an amount within the range of from about 0.1% to about 30% by weight b) the bulking agent or filler is present in an amount within the range of from about 10% to about 85% by weight; c) the binder, if present, is present in an amount within the range of from about I % to about 10% by weight; d) the disintegrant, if present, is in an amount within the range of front about 0.25% to about 10% by weight; e) the glidant and/or anti-adherent, if present, is in an amount within hc range of from about 1% to about 15% by weight; and f) the lubricant, if present, is in an amount within the range of from about 0.2% to about 2% by weight, all of the above % by weight being based on the weight of the stock granulation. [0036] In one embodiment, the medicament in the pharmaceutical formulations has 90% of the particles smaller than 200 micrometers. In another embodiment, the medicament has 90% of its particles smaller than 100 micrometers. In another embodiment, the medicament has 90% of its particles smaller than 50 micrometers. -11- Dapagliflozin propylene glycol hydrate can be milled or micronized as needed to obtain the above mentioned characteristics. [00371 Examples of bulking agents or fillers suitable for use herein include, but are not limited to, cellulose derivatives, such as microcrystalline cellulose or wood cellulose, lactose, sucrose, starch, pregelatinized starch, dextrose, mannitol, fructose, xylitol, sorbitol, corn starch, modified corn starch, inorganic salts such as calcium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, dextrin/dextrates, maltodextrin, compressible sugars, and other known bulking agents or fillers, and/or mixtures of two or more thereof Several types of microcrystalline cellulose are suitable for use in the fonnulations described herein, for example, microcrystalline cellulose selected from the group consisting of Avicel@ types: PH101, PH102, PH103, PH105, PH 112, PH 113, PH200, PH301, and other types of microcrystalline cellulose, such as silicified microcrystalline cellulose. Several types of lactose are suitable for use in the fonnulations described herein, for example, lactose selected from the group consisting of anhydrous lactose, lactose monohydrate, lactose fast flo, directly compressible anhydrous lactose, and modified lactose monohydrate. In one embodiment of the invention, the bulking agent of the stock granulation is microcrystalline cellulose and/or lactose. Lactose is particularly useful for tablet formulation. 100381 Examples of binders suitable for use herein include, but are not limited to, hydroxypropyl cellulose, corn starch, pregelatinized starch, modified corn starch, polyvinyl pyrrolidone (PVP) (typical molecular weight ranging from about 5,000 to about 1,000,000, preferably about 40,000 to 50,000), hydroxypropyl methylcellulose (HPMC), lactose, gum acacia, ethyl cellulose, cellulose acetat , as well as a wax binder such as carnauba wax, paraffin, spermaceti, polyethylene or microcrystalline wax, as well as other conventional binding agents and/or mixtures of two or more thereof In one embodiment of the invention, the binding agent, if present, of the stock granulation is pregelatinized starch. [00391 Examples of disintegrants suitable for use herein include, but are not limited to, croscarmellose sodium, crospovidone, starch, potato starch, pregelatinized starch, corn starch, sodium starch glycolate, microcrystalline 4-1 cellulose, low substituted hydroxypropyl cellulose and other known disintegrants. Several specific types of disintegrant are suitable for use in the formulations described herein. For example, any grade of crospovidone can be used, including for example crospovidone XL-10, and includes members selected from the group consisting of Kollidon CL*, Polyplasdone XL, Kollidon CL-M*, Polyplasdone
XL
10*, and Polyplasdone INF-10*. In one embodiment, the disintegrant, if present, of the stock granulation is sodium starch glycolate, croscarmellose sodium and/or crospovidone. In one embodiment, the disintegrant is sodium starch glycolate. In another embodiment, the disintegrant is croscarmellose sodium and/or crospovidone, which are particularly useful for tablet formulation. In one specific embodiment, the disintegrant is crospovidone XL- 10 with peroxide levels below 400 parts per million (ppm). These materials are also referred to as insoluble polyvidone, insoluble PVP, crosslinked PVP, and PVPP. The crospovidone can be substituted with croscarmellose sodium, sodium starch glycolate, or pregelatinized starch (at, for example, a 5-10% concentration). [00401 Examples of lubricants suitable for use herein include, but are not limited to, magnesium stearate, zinc stearate, calcium stearate, talc, carnauba wax, stearic acid, palmitic acid, sodium stearyl fumarate sodium laurel sulfate, glyceryl palmitostearate, palnitic acid, myristic acid and hydrogenated vegetable oils and fats, as well as other known lubricants, and/or mixtures of two or more thereof In one embodiment, the lubricant, if present, of the stock granulation is magnesium stearate. 10041] Examples of glidants and/or anti-adherents suitable fbr use herein include but are not limited to, silicon dioxide (generally), colloidal silicon dioxide, magnesium silicate, magnesium trisilicate, talc, and other forms of silicon dioxide, such as aggregated silicates and hydrated silica. [00421 In one embodiment of the stock granulation, the bulking agent is microcrystalline cellulose and/or lactose monohydrate, the binder, if present, is pregelatinized starch, the disintegrant, if present, is sodium starch glycolate, croscarmellose sodium and/or crospovidone, the lubricant, if present, is magnesium 413stearate and the glidant and/or anti-adherent, if present, is silicon dioxide and/or talc. 100431 In one embodiment, the tablet or capsule has a protective outer layer. The protective outer layer of the tablet or capsule, where present, can include from about 10% to about 95% of polymer based on the weight of the coating layer, and can be prepared employing conventional procedures. In one embodiment, the outer layer of the tablet or capsule includes from about 20% to about 90% of polymer based on the weight of the coating layer. The formulation can contain at least one coating layer polymer and a coating solvent, for example, water, which is used for processing and removed by drying. Suitable examples of polymer for the coating layer include, but are not limited to, hydroxypropyl methylcellulose, polyvinyl alcohol (PVA), ethyl cellulose, methacrylic polymers, hydroxypropyl cellulose, and starch. In one embodiment, the coating layer polymer is PVA. In another embodiment, the coating layer polymer is hydroxypropyl cellulose. Use of PVA allows for enhanced logo definition, film adhesion, and facilitates faster coating of the drug, the latter of which can be important for dapagliflozin formulations due to the temperature sensitivity of the compound. [00441 The coating can also optionally include a plasticizer of from about 0% to about 30% by weight, based on the weight of the coating layer. In one embodiment, the plasticizer is from about 15% to about 25% by weight of the coating layer. Suitable platicizers include, but are not limited to, triacetin, die hyl phthalate, tributyl sebacate, polyethylene glycol (PEG), glycerin, triacetin, and triaethyl citrate, for example. In one embodiment, the platicizer is polyethylene glycol of molecular weight 200 to 20,000. In another embodiment, the platicizer is polyethylene glycol of molecular weight 400 to 4,000. In another embodiment, the platicizer is polyethylene glycol of molecular weight 400. [00451 In another embodiment, the coating can also optionally include an anti adherent or glidant such as talc, fumed silica, or magnesium stearate, for example. In another embodiment, the coating can also optionally include an opacifying agent, such as titanium dioxide, for example. In yet another embodiment, the coating layer can also optionally include one or more colorants, for example, iron oxide based
-
colorant(s). Examples of commercially available coating material include Oppdry* HP and Opadry* II white. [00461 The pharmaceutical formulations disclosed herein can further comprise antioxidants and chelating agents. For example, the pharmaceutical formulations can comprise butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), propyl gallate (PG), sodium metabisulfite, ascorbyl palmitate, potassium inetabisulfite, disodium EDTA (ethylenediamine tetraacetic acid; also known as disodium edentate), EDTA, tartaric acid, citric acid, citric acid monohydrate, and sodium sulfite. In one embodiment, the foregoing compounds are included in the pharmaceutical formulations in amounts in the range of about 0.01% to about 5% w/w. In one specific embodiment, the pharmaceutical formulation includes BHA, BHT, or PG used at a range of about 0.02% to about 1% and disodium EDTA, citric acid, or citric acid monohydrate used at a range of about 2% to about 5%. In a preferred embodiment, the pharmaceutical formulation includes BHA used at about 0.05% w/w. [00471 The phannaceutical formulations of the invention as described above are prepared by mixing together dapagliflozin propylene glycol hydrate and one or more of the desired excipients described herein in any desired order, to form the stock granulation; and filling the capsules with or forming tablets from desired quantities of the stock granulation. The stock granulation, capsules and tablets of the invention can be prepared by a variety of processes and order of addition of excipients. The utility of these formulations is not limited to a specific dosage form or manufacturing process. For example, stock formulation tablets can be manufactured by wet granulation, dry granulation, direct blending or any other pharmaceutically acceptable process described herein or otherwise known in the art. 100481 The pharmaceutical fonnulations of the invention can be packaged in any packaging that facilitates stability of the drug formulation. For example, sealed high density polyethylene (HDPE) bottles containing silica gel desiccant or aluminum blister lined with PVC can be used. Use of such packaging helps to control unwanted oxidation of the product at room temperature. -15- 100491 Examples of certain specific embodiments of tablet and capsule formulations in accordance with the invention are set out below. Table . Tablet and Capsule Formulations Material Possible Range Preferred Range % by weight of tablet % by weight of tablet or capsule fill or capsule fill Dapagliflozin propylene 0.1 to 70% 0.1 to 30% glycol hydrate Bulking Agent/binder 1 to 95% 10 to 85% Anhydrous Lactose 0 to 95% 20 to 75% Microcrystalline 0 to 95% 20 to 75% cellulose Pregelatinized starch 0 to 95% 10 to 75% Disintegrant 0 to 20% 0.25 to 10% Croscarmellose sodium 0 to 20% 2 to 10% Crospovidone 0 to 12% 4 to 10% Sodium Starch O to20% 2 to 10% glycolate Lubricant 0.1 to 5% 0.2 to 2% Magnesium Stearate 0.1 to 5% 0.2 to 2% Anti adherent/glidant 0 to 10% 1 to 10% Tale, silicon dioxide more preferably 1 to 4% Outer Protective Coating % by weight of tablet or % by weight of tabletior Layer capsule fill capsule fill Coating polymer, and 0.5 to 50% 1 to 5% optional plasticizer(s), glidant(s), anti-tacking agent(s), and colorant(s) Table I. Granulation Composition (% w/w) for Tablets and Capsules Ingredient Possible Preferred Range range % by weight % by weight Dapagliflozin Propylene Glycol Hydrate 0.1-40 0.1-10 Microcrystalline Cellulose .s. s. Anhydrous Lactose 0-50 10-30 Crospovidone 1-15 3-10 Silicon Dioxide 0-6 0.5-4 -16 Magnesium Stearate 0.0-4.,0 0.5-2.0 q.s. refers to the quantity sufficient to make the granulation composition 100% w/w. 100501 A film coating for capsules or tablets of Table II comprises, for example, polyvinyl alcohol (PVA), titanium dioxide, polyethylene glycol, talc, and colorant. [0051] Tablets or capsules of various strengths (0.1 - 50mg ) can be prepared using different weights of the stock granulations described herein. [00521 The pharmaceutical formulation in the form of a tablet can be obtained by a process comprising the steps of: a) mixing the inactive ingredients with the medicament (Dapagliflozin propylene glycol hydrate) using a combination of blending and milling processes; b) formulating granules; c) drying and/or screening the granules; d) blending the granules; and e) tabletting the blend obtained in (d) into tablets. 10053] In one embodiment, step a) of the process employs impact milling and/or sizing equipment. In one embodiment, the granules in step b) of the process are formulated by dry granulation, wet granulation, or direct compression. In one embodiment, the granules are formulated by dry granulation. In one embodiment, the granules in step d) of the process are blended with a tableting aid or a lubricant and filler. [00541 The pharmaceutical formulation in the form of a capsule can be obtained by a process comprising the steps of: a) mixing the inactive ingredients with the medicament using a combination of blending and milling processes; b) formulating granules; c) drying and/or screening the granules; and (d) loading the granules into capsules. [0055] In one embodiment, step a) of the process employs impact milling and/or sizing equipment. In one embodiment, the granules in step b) of the process are formulated by dry granulation, wet granulation, or direct compression. In one embodiment, the granules are formulated by dry granulation. -17.
[0056] The dapagliflozin propylene glycol hydrate ((S) form can be prepared, for example, by a process as described in U.S. Application Serial No: 11/765,481, filed June 28, 2007, U.S. Publication No. 2008-0004336 Al, and provisional application No. 60/817,118 filed June 28, 2006. OEt CI HO ' ksH
*H
2 0 * HO HO\\ "'OH OH OH Compound la For example, dapagliflozin (S)-propylene glycol hydrate (Compound Ia) can be prepared by the following steps: providing a compound A (prepared as described in U.S. application Serial No. 10/745,075 filed December 23, 2003, Examples 17 to 20), of the structure (A); AcO O AcO % "OAc OAc Compound A treating compound A with an alcohol solvent, such as methanol or ethanol, and aqueous base, such as sodium hydroxide, and water, if necessary, under an inert atmosphere, and elevated temperature, if necessary; adding an acid, such as hydrochloric acid to neutralize the reaction mixture, to form compound I of the structure; 48.
OEt CI / HO ""OH H O\' "/0 H OH Compound I treating the reaction mixture containing compound I with an organic solvent, such as methyl t-butyl ether, an alkyl acetate, such as ethyl acetate, methyl acetate, isopropyl acetate, or butyl acetate, and (S)-propylene glycol; optionally adding seeds of(S) propylene glycol compound Ia (SC-3) to the mixture, to form dapagliflozin (S) propylene glycol compound la (SC-3 form). [00571 In another example, dapagliflozin propylene glycol hydrate can be prepared in a process comprising the step of reducing a compound of the structure (B) OEt C1 HO OOMe HO OH OH B to remove the methoxy group; treating compound B with a reducing agent, such as triethylsilyl hydride and an activating group which is a Lewis acid, such as BF 3 .Et 2 O, and an organic solvent, such as CH 3 CN, and water; separating out the compound of the structure (I); OEt C1 HO "41 " H O~ H OW ?"0 H OH and treating compound I with (S)-propylene glycol in the presence of a solvent, such as t-butylmethyl ether, and optionally with seeds of compound la (dapagliflozin
(S)
-1 9.
propylene glycol), to form a crystal slurry of compound Ia (dapagliflozin (S)-propylene glycol) and separating out compound Ia (dapagliflozin (S)-propylene glycol). [00581 The above process of the invention is a one-pot operation which minimizes the production of intermediates, resulting in improved yield and priority of the final crystalline compound Ia dapagliflozin(S)-propylene glycol. [0059] In carrying out the formation of compound Ia, the (S)-propylene glycol is employed in a molar ratio to compound I with the range of from about 0.9:1 to about 1.5:1. In one embodiment, the (S)-propylene glycol is employed in a molar ratio to compound I with the range of from about 0.98:1 to about 1.2:1. [0060] The activity of dapagliflozin or dapagliflozin propylene glycol hydrate can be determined using, for example, the assay system described below or any appropriate assay system known in the art. [0061] The mRNA sequence for human SGLT2 (GenBank #M95549) is cloned by reverse-transcription and amplification from human kidney mRNA, using standard molecular biology techniques. The cDNA sequence is stably transfected into CHO cells, and clones are assayed for SGLT2 activity essentially as described in Ryan et al., "HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney", Kidney International, 45:48-57 (1994). Evaluation of inhibition of SGLT2 activity in a clonally selected cell line is performed essentially as described in Ryan et al. (1994), with the following modifications. Cells are grown in 96-well plates for 2-4 days to 75,000 or 30,000 cells per well in F- 12 nutrient mixture (Ham's F-12), 10% fetal bovine serum, 300 ug/ml Geneticin and penicillin-streptomycin. At confluence, the cells are washed twice with 10 mM Hepes/Tris, pH 7.4, 137 mM N-methyl-D-glucamine, 5.4 mM KCI, 2.8 mM CaCl., 1.2 mM MgSO 4 Cells are then incubated with 10 ,M [ 4 C]AMG, and 10 uM inhibitor (final DMSO =0.5%) in 10 mM Hepes/Tris, pH 7.4, 137 mM NaCl, 5.4 mM KCI, 2.8 mM CaC2, 1.2 mM MgSO 4 at 37'C for 1.5 hours. Uptake assays are quenched with ice cold IX PBS containing 0.5 mM phlorizin, and cells are then lysed with 0.1% NaOH. After addition of MicroScint scintillation fluid, the cells are allowed to shake for 1 hour, and then [' 4 C]AMG (glucose analog a-methyl-D glucopyranoside) is quantitated on a TopCount scintillation counter. Controls are -20 performed with and without NaCl. For determination of ECso values, 10 inhibitor concentrations (dapagliflozin) are used over 2 log intervals in the appropriate response range, and triplicate plates are averaged across plates. 100621 The phannaceutical formulations of the present invention containing dapagliflozin propylene glycol hydrate possess activity as an inhibitor of the sodium dependent glucose transporters found in the intestine and kidney of mammals, is a selective inhibitor of renal SGLT2 activity, and therefore can be used in the treatment of diseases or disorders associated with SGLT2 activity. [00631 Accordingly, the pharmaceutical dapagliflozin propylene glycol hydrate formulations of the present invention can be administered to mammals, preferably humans, for the treatment of a variety of conditions and disorders associated with SGLT2 activity including, but not limited to, treating or delaying the progression or onset of diabetes (including Type I and Type I diabetes, impaired glucose tolerance, insulin resistance, and diabetic complications, such as nephropathy, retinopathy, neuropathy and cataracts), hyperglycemia, hyperinsulinemia, hypercholesterolemia, dyslipidemia, elevated blood levels of free fatty acids or glycerol, hyperlipidemia, hypertriglyceridemia, obesity, wound healing, tissue ischemia, atherosclerosis and hypertension. The formulations of the present invention can also be utilized to increase the blood levels of high density lipoprotein (HDL). In addition, the conditions, diseases, and maladies collectively referenced to as "Syndrome X" or Metabolic Syndrome as detailed in Johannsson, J. Clin. Endocrinol. Metab., 82, 727-34 (1997), can be treated employing the formulations of the present invention. [00641 In one embodiment, the invention provides the pharmaceutical dapagliflozin propylene glycol hydrate formulations of the invention for use in the treatment of type II diabetes. In another embodiment, the invention provides the pharmaceutical dapagliflozin propylene glycol hydrate formulations of the invention for use in delaying the progression or onset of type II diabetes. [00651 The invention further provides a method for treating or delaying the progression or onset of diseases or disorders associated with SGLT2 activity comprising administering to a mammalian species in need of such treatment a -21therapeutically effective amount ofthe pharmaceutical dapagliflozin propylene glycol hydrate formulation of the invention. In one embodiment, the invention provides a method for treating type II diabetes comprising administering to a mammalian species in need of such treatment a therapeutically effective amount of the pharmaceutical dapagliflozin propylene glycol hydrate formulation of the invention. In another embodiment, the invention provides a method for delaying the progression or onset of type II diabetes comprising administering to a mammalian species in need of such treatment a therapeutically effective amount of the pharmaceutical dapagliflozin propylene glycol hydrate formulation of the invention. [00661 In one embodiment, the invention provides the use of the pharmaceutical dapagliflozin propylene glycol hydrate formulation of the invention (including the stock granulation, capsules containing same, and tablets thereof) in the manufacture of a medicament for the treatment of type II diabetes. In another embodiment, the invention provides the use of the pharmaceutical dapagliflozin propylene glycol hydrate formulation of the invention in the manufacture of a medicament for delaying the progression or onset of type II diabetes. The invention also provides the pharmaceutical dapagliflozin propylene glycol hydrate formulation of the invention for use in therapy in treating or delaying the progression or onset of type II diabetes. [0067] Other therapeutic agent(s) suitable for combination with the formulations of the present invention include, but are not limited to, known therapeutic agents useful in the treatment of the aforementioned disorders associated with SGLT2 activity including: anti-diabetic agents; anti-hyperglycemic agents; hypolipidenic or lipid lowering agents; anti-obesity agents; anti-hypertensive agents and appetite suppressants. [0068] The invention further provides a method for treating or delaying the progression or onset of diseases or disorders associated with SGLT2 activity comprising administering to a mammalian species in need of such treatment a therapeutically effective amount of the pharmaceutical formulation of the invention and one or more of the following: anti-diabetic agent(s), anti-hyperglycemic 22a agent(s); hypolipidemic or lipid lowering agent(s); anti-obesity agent(s); anti hypertensive agent(s) and appetite suppressant(s). [00691 In one embodiment, the invention provides a method for treating type II diabetes comprising administering to a mammalian species in need of such treatment a therapeutically effective amount of the pharmaceutical formulation of the invention and one or more anti-diabetic agent(s). In another embodiment, the invention provides a method for delaying the progression or onset of type II diabetes comprising administering to a mammalian species in need of such treatment a therapeutically effective amount of the pharmaceutical formulation of the invention and one or more anti-diabetic agent(s). [0070] In another embodiment, the invention provides a method for treating or delaying the progression or onset of type II diabetes comprising administering to a mammalian species in need of such treatment a therapeutically effective amount of the pharmaceutical formulation of the invention and one or more of the following: anti-hyperglycemic agent(s); hypolipidemic or lipidlowering agent(s); anti-obesity agent(s); anti-hypertensive agent(s) and appetite suppressant(s). For example, the invention provides a method for treating or delaying the progression or onset of type II diabetes comprising administering to a mammalian species in need of such treatment a therapeutically effective amount of a pharmaceutical formulation of the invention and an anti-hyperglycemic agent(s). In another embodiment, the invention provides a method for treating or delaying the progression or onset of type II diabetes comprising administering to a mammalian species in need of such treatment a therapeutically effective amount of a pharmaceutical formulation of the invention and a hypolipidemic agent(s). In another embodiment, the invention provides a method for treating or delaying the progression or onset of type II diabetes comprising administering to a mammalian species in need of such treatment a therapeutically effective amount of a pharmaceutical formulation of the invention and an anti-obesity agent(s). In another embodiment, the invention provides a method for treating or delaying the progression or onset of type II diabetes comprising administering to a mammalian species in need of such treatment a therapeutically effective amount of a pharmaceutical formulation of the invention -23and an anti-hypertensive agent(s). In another embodiment, the invention provides a method for treating or delaying the progression or onset of type II diabetes comprising administering to a mammalian species in need of such treatment a therapeutically effective amount of a pharmaceutical formulation of the invention and an appetite suppressant(s). 10071] The invention provides the use of the pharmaceutical dapagliflozin propylene glycol hydrate formulations of the invention (including the stock granulation, capsules containing same, and tablets thereof) in the manufacture of a medicament for the treatment of diseases or disorders associated with SGLT2 activity, for example, Type I and Type II diabetes; impaired glucose tolerance; insulin resistance; and diabetic complications, such as nephropathy, retinopathy, neuropathy and cataracts; hyperglycemia; hyperinsulinemia; hypercholesteroleknia; dyslipidemia; elevated blood levels of free fatty acids or glycerol; hyperlipideniua; hypertriglyceridemia; obesity; wound healing; tissue ischenia; atherosclerosis; hypertension; and Syndrome X or Metabolic Syndrome. [0072] The invention provides the use of the combination of the pharmaceutical dapagliflozin propylene glycol hydrate formulations of the invention and one or more agents selected from the group consisting of anti-diabetic agents, anti hyperglycemic agents, hypolipidemic or lipid lowering agents, anti-obesity agents, anti-hypertensive agents, and appetite suppressants as a medicament for the treatment of diseases or disorders associated with SGLT2 activity, for example, Type I and Type II diabetes; impaired glucose tolerance; insulin resistance; and diabetic complications, such as nephropathy, retinopathy, neuropathy and cataracts; hyperglycemia; hyperinsulinemia; hypercholesterolernia; dyslipidemia; elevated blood levels of free fatty acids or glycerol; hyperlipidemia; hypertriglyceridenia; obesity; wound healing; tissue ischemia; atherosclerosis; hypertension; and Syndrome X or Metabolic Syndrome. [0073] In one embodiment, the invention provides the combination of the pharmaceutical dapagliflozin propylene glycol hydrate formulation of the invention and one or more anti-diabetic agents as a medicament for the treatment of type II diabetes. In another embodiment, the invention provides the combination of the -24 pharmaceutical dapagliflozin propylene glycol hydrate formulation of the invention and one or more anti-diabetic agents as a medicament for delaying the progression or onset of type II diabetes. In another embodiment, the invention provides the combination of the pharmaceutical dapagliflozin propylene glycol hydrate formulation of the invention and one or more anti-hyperglycemic agents as a medicament for the treatment of type II diabetes. In another embodiment, the invention provides the combination of the pharmaceutical dapagliflozin propylene glycol hydrate formulation of the invention and one or more anti-hyperglycemic agents as a medicament for delaying the progression or onset of type II diabetes. In another embodiment, the invention provides the combination of the phannaceutical dapagliflozin propylene glycol hydrate formulation of the invention and one or more hypolipidemic agents or lipid-lowering agents as a medicament for the treatment of type II diabetes. In another embodiment, the invention provides the combination of the pharmaceutical dapagliflozin propylene glycol hydrate formulation of the invention and one or more hypolipidemic agents or lipid-lowering agents as a medicament for delaying the progression or onset of type II diabetes. In another embodiment, the invention provides the combination of the pharmaceutical dapagliflozin propylene glycol hydrate formulation of the invention and one or more anti-obesity agents as a medicament for the treatment of type II diabetes. In another embodiment, the invention provides the combination of the pharmaceutical dapagliflozin propylene glycol hydrate formulation of the invention and one or more anti-obesity agents as a medicament for delaying the progression or onset of type II diabetes. In another embodiment, the invention provides the combination of the pharmaceutical dapagliflozin propylene glycol hydrate formulation of the invention and one or more anti-hypertensive agents as a medicament for the treatment of type II diabetes. In another embodiment, the invention provides the combination of the pharmaceutical dapagliflozin propylene glycol hydrate formulation of the invention and one or more anti-hypertensive agents as a medicament for delaying the progression or onset of type II diabetes. In another embodiment, the invention provides the combination of the pharmaceutical dapagliflozin propylene glycol hydrate formulation of the invention and one or more appetite suppressants as a medicament for the treatment of type II diabetes. In another embodiment, the invention provides the combination of the pharmaceutical dapagliflozin propylene glycol hydrate formulation of the invention and one or more appetite suppressants as a medicament for delaying the progression or onset of type II diabetes. 100741 The invention provides the use of the pharmaceutical dapagliflozin propylene glycol hydrate formulation of the invention in the manufacture of a medicament for treating or delaying the progression or onset of Type I and Type II diabetes, impaired glucose tolerance, insulin resistance, nephropathy, retinopathy, neuropathy, cataracts, hyperglycemia, hyperinsulineia, hypercholesterolemia, dyslipideria, elevated blood levels of free fatty acids or glycerol, hyperlipidemia, hypertriglyceridemia, obesity, wound healing, tissue ischemia, atherosclerosis hypertension, or Syndrome X (Metabolic Syndrome), in which such treatment comprises a combination with one or more agents selected from the group consisting of anti-diabetic agents, anti-hyperglycemic agents, hypolipidenic or lipid lowering agents, anti-obesity agents, anti-hypertensive agents, and appetite suppressants, for concurrent or sequential use, in any order. [00751 In one embodiment, the invention provides the use of the pharmaceutical dapagliflozin propylene glycol hydrate fonnulation of the invention in the manufacture of a medicament for the treatment of type I diabetes, in which such treatment comprises a combination with one or more anti-diabetic agents, for concurrent or sequential use, in any order. In another embodiment, the invention provides the use of the pharmaceutical dapagliflozin propylene glycol hydrate formulation of the invention in the manufacture of a medicament for delaying the progression or onset of type II diabetes, in which such treatment comprises a combination with one or more anti-diabetic agents, for concurrent or sequential use, in any order. In another embodiment, the invention provides the use of the pharmaceutical dapagliflozin propylene glycol hydrate formulation of the invention in the manufacture of a medicament for the treatment of type II diabetes, in which such treatment comprises a combination with one or more anti-hyperglycenic agents, for concurrent or sequential use, in any order. In another embodiment, the invention provides the use of the pharmaceutical dapagliflozin propylene glycol -26 hydrate formulation of the invention in the manufacture of a medicament for delaying the progression or onset of type II diabetes, in which such treatment comprises a combination with one or more anti-hyperglycemic agents, for concurrent or sequential use, in any order. In another embodiment, the invention provides the use of the pharmaceutical dapagliflozin propylene glycol hydrate formulation of the invention in the manufacture of a medicament for the treatment of type II diabetes, in which such treatment comprises a combination with one or more hypolipidemic agent or lipid-lowering agents, for concurrent or sequential use, in any order. In another embodiment, the invention provides the use of the pharmaceutical dapagliflozin propylene glycol hydrate fonrmulation of the invention in the manufacture of a medicament for delaying the progression or onset of type II diabetes, in which such treatment comprises a combination with one or more hypolipidemic agents or lipid-lowering agents, for concurrent or sequential use, in any order. In another embodiment, the invention provides the use of the pharmaceutical dapagliflozin propylene glycol hydrate formulation of the invention in the manufacture of a medicament for the treatment of type II diabetes, in which such treatment comprises a combination with one or more anti-obesity agents, for concurrent or sequential use, in any order. In another embodiment, the invention provides the use of the pharmaceutical dapagliflozin propylene glycol hydrate formulation of the invention in the manufacture of a medicament for delaying the progression or onset of type II diabetes, in which such treatment comprises a combination with one or more anti-obesity agents, for concurrent or sequential use, in any order. In another embodiment, the invention provides the use of the pharmaceutical dapagliflozin propylene glycol hydrate formulation of the invention in the manufacture of a medicament for the treatment of type II diabetes, in which such treatment comprises a combination with one or more anti-hypertensive agents, for concurrent or sequential use, in any order. In another embodiment, the invention provides the use of the phannaceutical dapagliflozin propylene glycol hydrate formulation of the invention in the manufacture of a medicament for delaying the progression or onset of type II diabetes, in which such treatment comprises a combination with one or more anti-hypertensive agents, for concurrent or sequential use, in any order. In another embodiment, the invention provides the use of the pharmaceutical dapagliflozin propylene glycol hydrate fonnulation of the invention in the manufacture of a medicament for the treatment of type II diabetes, in which such treatment comprises a combination with one or more appetite suppressants, for concurrent or sequential use, in any order. In another embodiment, the invention provides the use of the pharmaceutical dapagliflozin propylene glycol hydrate formulation of the invention in the manufacture of a medicament for delaying the progression or onset of type II diabetes, in which such treatment comprises a combination with one or more appetite suppressants, for concurrent or sequential use, in any order. [00761 The formulations of the invention in the form of capsules or tablets containing dapagliflozin propylene glycol hydrate can be administered in dosages of about 0.1 mg to about 750 mg per day, in single or divided doses or multiple doses which can be administered 1 to 4 times daily. In one embodiment, the formulations of the invention in the form of capsules or tablets containing dapagliflozin propylene glycol hydrate is administered in dosages of about 0.2 mg to about 600 mg per day, in single or divided doses or multiple doses which can be administered I to 4 times daily. In another embodiment, the formulations of the invention in the form of capsules or tablets containing dapagliflozin propylene glycol hydrate is administered in dosages of from about 0.5 mg to about 100 mg per day, in single or divided doses or multiple doses which can be administered I to 4 times daily. 100771 The present invention includes within its scope pharmaceutical formulations containing, as an active ingredient, a therapeutically effective amount of dapagliflozin propylene glycol hydrate, in combination with one or more bulking agents and optionally a pharmaceutical carrier or diluents, as described. Optionally, the formulations of the present invention can be utilized as an individual treatment, or utilized in combination with one or more other therapeutic agent(s) in the same dosage fonrm (fixed dosage) or separate dosage forms. [00781 Other therapeutic agent(s) suitable for combination with the formulations of the present invention include, but are not limited to, known therapeutic agents useful in the treatment of the aforementioned disorders including: -2g anti-diabetic agents; anti-hyperglycemic agents; hypolipidemic/lipid lowering agents; anti-obesity agents; anti-hypertensive agents and appetite suppressants. [00791 Examples of suitable anti-diabetic agents for use in combination with the fornulations of the present invention include, but are not limited to, biguanides (e.g., metformin or phenforniin), glucosidase inhibitors (e.g., acarbose or miglitol), insulins (including insulin secretagogues or insulin sensitizers), meglitinides (e.g., repaglinide), sulfonylureas (e.g., glimepiride, glyburide, gliclazide, chlorproparide and glipizide), biguanide/glyburide combinations (e.g., Glucovance*), thiazolidinediones (e.g., troglitazone, rosiglitazone and pioglitazone), PPAR-alpha agonists, PPAR-gamma agonists, PPAR alpha/gamma dual agonists, glycogen phosphorylase inhibitors, inhibitors of fatty acid binding protein (aP2), glucagon-like peptide-1 (GLP-1) and other agonists of the GLP-1 receptor, and dipeptidyl peptidase IV (DPP4) inhibitors. [0080] Other suitable thiazolidinediones include, but are not limited to, MCC 555 (disclosed in U.S. Patent No. 5,594,016, Mitsubishi), faraglitazar (GI-262570, Glaxo-Wellcome), englitazone (CP-68722, Pfizer) or darglitazone (CP-86325, Pfizer; isaglitazone, MIT/Johnson& Johnson), reglitazar (JTT-501, (JPNT/Pharmacia & Upjohn), rivoglitazone (R- 119702, Sankyo/WL), liraglutide (NN-2344, Dr. Reddy/NN), and (Z)-1,4-bis-4-[(3 ,5-dioxo-1,2,4-oxadiazolidin-2-yl methyl)]phenoxybut-2-ene (YM-440, Yamanouchi). 100811 Examples of PPAR-alpha agonists, PPAR-gamma agonists and PPAR alpha/gamma dual agonists include, but are not limited to, muraglitazar, peliglitazar tesaglitazar AR-H039242 (Astra/Zeneca), GW-501516 (Glaxo-Wellcome), KRP297 (Kyorin Merck), as well as those disclosed by Murakami et al, "A Novel Insulin Sensitizer Acts As a Coligand for Peroxisome Proliferation - Activated Receptor Alpha (PPAR alpha) and PPAR gamma. Effect on PPAR alpha Activation on Abnormal Lipid Metabolism in Liver of Zucker Fatty Rats", Diabetes 47, 1841-1847 (1998); WO 01/21602 and in U.S. Patent No. 6,414,002 and U.S Patent No. 6,653,314, the disclosures of which are incorporated herein by reference in their entireties, employing dosages as set out therein. In one embodiment, the -29.
compounds designated as preferred in the cited references are preferred for use herein. 100821 Suitable aP2 inhibitors include, but are not limited to, those disclosed in U.S. application Serial No. 09/391,053, filed September 7, 1999, and in U.S. Patent No. 6,548,529, the disclosures of which are incorporated herein by reference in their entireties, employing dosages as set out therein. [0083] Suitable DPP4 inhibitors include, but are not limited to, those disclosed in W099/38501, W099/46272, W099/67279 (PROBIODRUG), W099/67278 (PROBIODRUG), W099/61431 (PROBIODRUG), NVP-DPP728A (1-[[[2-[(5 cyanopyridin-2-yl)amino]ethyl] amino] acetyl]-2-cyano-(S)-pyrrolidine) (Novartis) as disclosed by Hughes et al, Biochemistry, 38(36), 11597-11603, 1999, TSL-225 (tryptophyl-1,2,3, 4 -tetrahydroisoquinoline-3-carboxylic acid (disclosed by Yamada et al, Bioorg. & Med. Chem. Lett. 8 (1998) 1537-1540), 2-cyanopyrrolidides and 4 cyanopyrrolidides, as disclosed by Ashworth et al, Bioorg. & Med. Chem. Lett., Vol. 6, No. 22, pp 1163-1166 and 2745-2748 (1996),.the compounds disclosed in U.S. application Serial No. 10/899,641, WO 01/68603 and U.S. patent 6,395,767, all of which are incorporated herein by reference in their entireties, employing dosages as set out in the above references. In one embodiment, the DPP4 inhibitor is saxagliptin. [00841 Other suitable meglitinides include nateglinide (Novartis) or KAD 1229 (PF/Kissei). [0085] Examples of suitable anti-hyperglycemic agents for use in combination with the formulations of the present invention include, but are not limited to, glucagon-like peptide-1 (GLP-1) such as GLP-1(1-36) amide, GLP-1(7-36) aide, GLP-1(7-37) (as disclosed in U.S. Patent No. 5,614,492, incorporated herein by reference in its entirety), as well as exenatide (Amylin/Lilly), LY-315902 (Lilly), MK-0431 (Merck), liraglutide (NovoNordisk), ZP- 10 (Zealand Pharmaceuticals A/S), CJC- 1131 (Conjuchem Inc), and the compounds disclosed in WO 03/033671, incorporated herein by reference in its entirety. [0086] Examples of suitable hypolipidemic/lipid lowering agents for use in combination with the formulations of the present invention include one or more -30.
MTP inhibitors, HMG CoA reductase inhibitors, squalene synthetase inhibitors, fibric acid derivatives, ACAT inhibitors, lipoxygenase inhibitors, cholesterol absorption inhibitors, ileal Na*Ibile acid co-transporter inhibitors, up-regulators of LDL receptor activity, bile acid sequestrants, cholesterol ester transfer protein (e.g., CETP inhibitors, such as torcetrapib (CP-529414, Pfizer) and JTT-705 (Akros Pharma)), PPAR agonists (as described above) and/or nicotinic acid and derivatives thereof The hypolipidemic agent can be an up-regulator of LD2 receptor activity, such as 1(3H)-isobenzofuranone,3-(13-hydroxy- I 0-oxotetradecyl)-5,7-dimethoxy (MD-700, Taisho Pharmaceutical Co. Ltd) and cholestan-3-ol,4-(2-propenyl) (3a,4a,5a)- (LY295427, Eli Lilly). Preferred hypolipidemic agents include pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin, atavastatin and rosuvastatin (ZD-4522), for example. [00871 Examples of MTP inhibitors that can be employed as described above include, but are not limited to, those disclosed in U.S. Patent No. 5,595,872, U.S. Patent No. 5,739,135, U.S. Patent No. 5,712,279, U.S. Patent No. 5,760,246, U.S. Patent No. 5,827,875, U.S. Patent No. 5,885,983 and U.S. Patent No. 5,962,440, all of which are incorporated herein by reference in their entireties. [00881 Examples of HMG CoA reductase inhibitors that can be employed in combination with the formulations of the invention include, but are not limited to, mevastatin and related compounds, as disclosed in U.S. Patent No. 3,983,140, lovastatin (mevinolin) and related compounds, as disclosed in U.S. Patent No. 4,231,938, pravastatin and related compounds, such as disclosed in U.S. Patent No. 4,346,227, simvastatin and related compounds, as disclosed in U.S. Patent Nos. 4,448,784 and 4,450,171. Other suitable HMG CoA reductase inhibitors that can be employed herein include, but are not limited to, fluvastatin, disclosed in U.S. Patent No. 5,354,772, cerivastatin, as disclosed in U.S. Patent Nos. 5,006,530 and 5,177,080, atorvastatin, as disclosed in U.S. Patent Nos. 4,681,893, 5,273,995, 5,385,929 and 5,686,104, atavastatin (Nissan/Sankyo's nisvastatin (NK-104)), as disclosed in U.S. Patent No. 5,011,930, rosuvastatin (Shionogi-Astra/Zeneca
(ZD
4522)), as disclosed in U.S. Patent No. 5,260,440, and related statin compounds disclosed in U.S. Patent No. 5,753,675, pyrazole analogs of mevalonolactone -31derivatives, as disclosed in U.S. Patent No. 4,613,610, indene analogs of mevalonolactone derivatives, as disclosed in PCT application WO 86/03488, 6-[2 (substituted-pyrrol- I -yl)-alkyl)pyran-2-ones and derivatives thereof, as disclosed in U.S. Patent No. 4,647,576, Searle's SC-45355 (a 3-substituted pentanedioic acid derivative) dichloroacetate, imidazole analogs ofmevalonolactone, as disclosed in PCT application WO 86/07054, 3 -carboxy-2-hydroxy-propane-phosphonic acid derivatives, as disclosed in French Patent No. 2,596,393, 2,3-disubstituted pyrrole, furan and thiophene derivatives, as disclosed in European Patent Application No. 0221025, naphthyl analogs of mevalonolactone, as disclosed in U.S. Patent No. 4,686,237, octahydronaphthalenes, such as disclosed in U.S. Patent No. 4,499,289, keto analogs ofnmevinolin (lovastatin), as disclosed in European. Patent Application No.0142146 A2, and quinoline and pyridine derivatives, as disclosed in U.S. Patent No. 5,506,219 and 5,691,322. All of the cited references are incorporated herein by reference in their entireties. In addition, phosphinic acid compounds useful in inhibiting HMG CoA reductase, such as those disclosed in GB 2205837, are suitable for use in combination with the formulations of the present invention. [00891 Examples of squalene synthetase inhibitors suitable for use herein include, but are not limited to, a-phosphono-sulfonates disclosed in U.S. Patent No. 5,712,396, those disclosed by Biller et al., J. Med. Chem., 1988, Vol. 31, No. 0, pp. 1869-1871, including isoprenoid (phosphinyl-methyl)phosphonates, as well as other known squalene synthetase inhibitors, for example, as disclosed in U.S. Patent No. 4,871,721 and 4,924,024 and in Biller, S.A., Neuenschwander, K., Ponpipom, M.M., and Poulter, C.D., Current Pharmaceutical Design, 2, 1-40 (1996). Other squalene synthetase inhibitors suitable for use herein include the terpenoid pyrophosphates disclosed by P. Ortiz de Montellano et al, J. Med. Chem., 1977, 20, 243-249; the farnesyl diphosphate analog A and presqualene pyrophosphate
(PSQ
PP) analogs as disclosed by Corey and Volante, J. Am. Chem. Soc., 1976, 98, 1291-1293; phosphinylphosphonates reported by McClard, R. W. et al, J.A. C. S., 1987, 109, 5544; and cyclopropanes reported by Capson, T.L., PhD dissertation, June, 1987, Dept. Med. Chem. U of Utah, Abstract, Table of Contents, pp 16, 17, -32 40-43, 48-51, Summary. All of the cited references are incorporated herein by reference in their entireties. [00901 Examples of fibric acid derivatives that can be employed in combination the formulations of the invention include, but are not limited to, fenofibrate, gemfibrozil, clofibrate, bezafibrate, ciprofibrate, clinofibrate and the like, probucol, and related compounds, as disclosed in U.S. Patent No. 3,674,836 , bile acid sequestrants, such as cholestyrantine, colestipol and DEAE-Sephadex (Secholex*, Policexide*), as well as lipostabil (Rhone-Poulenc), Eisai E-5050 (an N-substituted ethanolamine derivative), imanixil (HOE-402), tetrahydrolipstatin (THL), istigmastanylphos-phorylcholine (SPC, Roche), aininocyclodextrin (Tanabe Seiyoku), Ajinomoto AJ-814 (azulene derivative), melinamide (Sumitomo), Sandoz 58-035, American Cyanamid CL-277,082 and CL-283,546 (disubstituted urea derivatives), nicotinic acid, acipimox, acifran, neomycin, p-aminosalicylic acid, aspirin, poly(diallylmethylamine) derivatives, such as disclosed in U.S. Patent No. 4,759,923, quaternary amine poly(diallyldimethylammoiiuim chloride) and ionenes, such as disclosed in U.S. Patent No. 4,027,009, and other known serum cholesterol lowering agents. In one embodiment, the fibric acid derivative is probucol or gemfibrozil. All of the cited references are incorporated herein by reference in their entireties. [0091] Examples of ACAT inhibitors that can be employed in combination with the formulations of the invention include, but are not limited to, those disclosed in Drugs of the Future 24, 9-15 (1999), (Avashnibe); "The ACAT inhibitor, Cl-101l is effective in the prevention and regression of aortic fatty streak area in hamsters", Nicolosi et al, Atherosclerosis (Shannon, Irel). (1998), 137(1), 77-85; "The phannacological profile of FCE 27677: a novel ACAT inhibitor with potent hypolipidemic activity mediated by selective suppression of the hepatic secretion of ApoB 1 00-containing lipoprotein", Ghiselli, Giancarlo, Cardiovasc. Drug Rev. (1998), 16(1), 16-30; "RP 73163: a bioavailable alkylsulfinyl-diphenylimidazole ACAT inhibitor", Smith, C., et al, Bioorg. Med. Chem. Lett. (1996), 6(1), 47-50; "ACAT inhibitors: physiologic mechanisms for hypolipidemic and anti atherosclerotic activities in experimental animals", Krause et al, Editor(s): Ruffolo, -33.
Robert R., Jr.; Hollinger, Minfred A., Inflammation: Mediators Pathways (1995), 173-98, Publisher: CRC, Boca Raton, Fla.; "ACAT inhibitors: potential anti atherosclerotic agents", Sliskovic et al, Curr. Med. Chem. (1994), 1(3), 204-25; "Inhibitors of acyl-CoA:cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. The first water-soluble ACAT inhibitor with lipid regulating activity. Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). Development of a series of substituted N-phenyl-N'-[(1 phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity", Stout et al, Chemtracts: Org. Chem. (1995), 8(6), 3 59-62, or TS-962 (Taisho Pharmaceutical Co. Ltd). All of the cited references are incorporated herein by reference in their entireties. [0092] Examples of suitable cholesterol absorption inhibitors for use in combination with the formulations of the invention include, but are not limited to, SCH48461 (Schering-Plough), as well as those disclosed in Atherosclerosis 115, 45-63 (1995) and J. Med. Chem. 41, 973 (1998), incorporated herein by reference in its entirety. [00931 Examples of suitable ileal Na'/bile acid co-transporter inhibitors for use in combination with the formulations of the invention include, but are not limited to, compounds as disclosed in Drugs of the Future, 24, 425-430 (1999), incorporated herein by reference in its entirety. [0094] Examples of lipoxygenase inhibitors that can be employed in combination with the formulations of the invention include, but are not limited to, 15-lipoxygenase (1 5-LO) inhibitors, such as benzimidazole derivatives, as disclosed in WO 97/12615, 15-LO inhibitors, as disclosed in WO 97/12613, isothiazolones, as disclosed in WO 96/38144, and 15-LO inhibitors, as disclosed by Sendobry et al "Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15 lipoxygenase inhibitor lacking significant antioxidant properties", Brit. J. Pharmacology (1997) 120, 1199-1206, and Cornicelli et al., "I5-Lipoxygenase and its Inhibition: A Novel Therapeutic Target for Vascular Disease", Current Pharmaceutical Design, 1999, 5, 11-20. All of the cited references are incorporated herein by reference in their entireties. -34 [0095] Examples of suitable anti-hypertensive agents for use in combination with the formulations of the present invention include, but are not limited to, beta adrenergic blockers, calcium channel blockers (L-type and T-type; e.g. diltiazem, verapamil, nifedipine, amlodipine and mybefradil), diuretics (e.g., chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichloromethiazide, polythiazide, benzthiazide, ethacrynic acid tricrynafen, chlorthalidone, furosemide, musolimine, bumetanide, triamtrenene, amiloride, spironolactone), renin inhibitors, ACE inhibitors (e.g., captopril, zofenopril, fosinopril, enalapril, ceranopril, cilazopril, delapril, pentopril, quinapril, ramipril, lisinopril), AT-1 receptor antagonists (e.g., losartan, irbesartan, valsartan), ET receptor antagonists (e.g., sitaxsentan, atrsentan and compounds disclosed in U.S. Patent Nos. 5,612,359 and 6,043,265), Dual ET/All antagonist (e.g., compounds disclosed in WO 00/01389), neutral endopeptidase (NEP) inhibitors, vasopepsidase inhibitors (dual NEP-ACE inhibitors) (e.g., omapatrilat and gemopatrilat), and nitrates. All of the cited references are incorporated herein by reference in their entireties. 100961 Examples of suitable anti-obesity agents for use in combination with the formulations of the present invention include, but are not limited to, beta 3 adrenergic agonists, lipase inhibitors, serotonin (and dopamine) reuptake inhibitors, thyroid receptor beta drugs, 5HT2C agonists, (such as Arena APD-356); MCHRl antagonists, such as Synaptic SNAP-7941 and Takeda T-226926, melanocortin receptor (MC4R) agonists, melanin-concentrating hormone receptor (MCHR) antagonists (such as Synaptic SNAP-7941 and Takeda T-226926), galanin receptor modulators, orexin antagonists, CCK agonists, NPYI or NPY5 antagonist, NPY2 and NPY4 modulators, corticotropin releasing factor agonists, histamine receptor-3 (H3) modulators, II -beta-HSD- 1 inhibitors, adinopectin receptor modulators, monoamine reuptake inhibitors or releasing agents, ciliary neurotrophic factors (CNTF, such as AXOKINE* by Regeneron), BDNF (brain-derived neurotrophic factor), leptin and leptin receptor modulators, cannabinoid- 1 receptor antagonists (such as SR-141716 (Sanofi) or SLV-319 (Solvay)), and anorectic agents. -35 [00971 Beta 3 adrenergic agonists that can be optionally employed in combination with formulations of the present invention include, but are not limited to, AJ9677 (Takeda/Dainippon), L750355 (Merck), CP331648 (Pfizer,) or other known beta 3 agonists, as disclosed in U.S. Patent Nos. 5,541,204, 5,770,615, 5,491,134, 5,776,983 and 5,488,064, all of which are incorporated herein by reference in their entireties. 10098] Examples of lipase inhibitors that can be employed in combination with formulations of the present invention include, but are not limited to, orlistat and ATL-962 (Alizyme). [0099] Serotonin (and dopamine) reuptake inhibitors (or serotonin receptor agonists) that can be employed in combination with the formulations of the present invention include, but are not limited to, BVT-933 (Biovitrum), sibutramine, topiramate (Johnson & Johnson) and axokine (Regeneron). [00100] Examples of thyroid receptor beta compounds that can be employed in combination with fonnulations of the present invention include, but are not limited to, thyroid receptor ligands, such as those disclosed in WO 97/21993 (U. Cal SF), WO 99/00353 (KaroBio) and WO 00/039077 (KaroBio), incorporated herein by reference it their entireties. [001011 Examples ofmonoamine reuptake inhibitors that can be employed in combination with the formulations of the present invention include, but are not limited to, fenfluramine, dexfenfluramine, fluvoxamine, fluoxetine, paroxetine, sertraline, chlorphentermine, cloforex, clortermine, picilorex, sibutramine, dexamphetamine, phentermine, phenylpropanolamine and mazindol. [00102] Anorectic agents that can be employed in combination with the formulations of the present invention include, but are not limited to, topiramate (Johnson & Johnson), dexamphetamine, phentermine, phenylpropanolamine and mazindol. 1001031 The aforementioned patents and patent applications are incorporated herein by reference. [00104] Where any of the formulations of the invention are used in combination with other therapeutic agent(s), the other therapeutic agent(s) can be used, for -36.
example, in the amounts indicated in the Physician's Desk Reference, as in the cited patents and patent applications set out above, or as otherwise known and used by one of ordinary skill in the art. [00105] Where any of the formulations of the invention are used in combination with other therapeutic agent(s), each of the compounds of the combination can be administered simultaneously or sequentially and in any order, and the components can be administered separately or as a fixed combination, in jointly therapeutically effective amounts, for example, in daily dosages as described herein. In one embodiment of the invention, a fixed combination of the invention can be prepared by mixing a dry granulation of the dapagliflozin or dapagliflozin propylene glycol hydrate formulation of the invention and a dry granulation of the other therapeutic agent(s) and filling the mixture into capsules of desired size, shape, color, or other characteristics, or compressed to form tablets. [001061 While this invention has been particularly shown and described with references to preferred embodinents thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims. It will also be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims. 100107] The following examples are provided to describe the invention in further detail. These examples, which set forth the best mode presently contemplated Ibr carrying out the invention, are intended to illustrate and not to limit the invention. The present invention is directed to pharmaceutical formulations comprising dapagliflozin propylene glycol hydrate, as defined in the claims. The examples which follow also refer to formulations comprising free dapagliflozin, which are not within the scope of the claims but are retained herein for technical information. EXAMPLES [00108] The following working Examples are illustrative of the present invention. All temperatures are expressed in degrees Centigrade unless otherwise indicated. -37.
Example 1: Preparation of dapagliflozin (compound 1) 1001091 The preparation of compounds of structure I is generally described in U.S. Patent 6,414,126, and specifically described in Scheme I and Example 1 of U.S. Patent 5,515,117, both of which are incorporated by reference herein in their entireties. Stable forms of compounds of structure (I) can be crystallized as solvates (e.g., hydrates) or complexes. Example 2A: Preparation of dapagliflozin (S)-propylene glycol hydrate (la) 100110] The preparation of structure la is described and depicted schematically below. AcO O, OEt on Ho O OEt r -TI Cl -- ,..,O~t 1) 4- 4.5 eq. CI O 0 NaOH (as IN i I Ac--,-solution) HO'Y N1 I N + 4 . q AcO >'OAc methanol HO" "'OH NaOAc OAc OH Compound A Compound I OEl 1) Isopropyl acetate, I eq. (S)-PG HO'* 0 C H 2) Cyclohexane H OH H 2 0 HO H OH Ia (S)-propylene glycol form SC-3 [00111] Compound A can be prepared as described in Example 1, Part E of U.S. Patent 6,515,117. 100112] A 1 O-L glass reactor equipped with a thermocouple and a nitrogen inlet was charged with MeOH (1.25 L), deionized water (3.6 L) followed by 50% aqueous NaOH (205.9 ml, 3.899 mol). The residual solution of NaOH in the measuring cylinder was transferred with water (94 ml) to the reaction vessel. Compound A (503.11 g, 0.872 mol) was added and the mixture was stirred and heated to -68*C over 1.5 hour. After 1 hour, the circulation bath temperature was lowered from 80*C to 70"C; internal temperature became 65*C. After a total of 3 -38.
hours, HPLC indicated completion of reaction, Compound I AP -99.5. (HPLC: Column: YMC ODS-A (C-1 8) S3, 4.6 x 50 mm. Solvent A: 0.2% aq. H 3 PO4 Solvent B: 90% CH 3 CN/10%H 2 0 Start %B = 0, final %B = 100 Gradient time 8 min; hold time 3 minutes. Integration stop time 11.0 minutes. Flow rate 2.5 ml/minute. UV wave length 220 un.) [001131 After the mixture was cooled to 25*C, isopropyl acetate (2.5 L) was added. The mixture was stirred for 10 minutes and then the aqueous layer was separated (pH = 12.5) and organic layer was washed with water (I L). During this wash the pH of the biphasic system was adjusted to 6.0 with concentrated HCl (5.0 ml) and then the aqueous layer was separated. Neutralization before phase split was done to prevent contamination of the product with NaOH. The (S)-propylene glycol structure prepared without neutralization was slightly basic [pH 8.3 of a suspension sonicated in water (--20 mg/mi)]. [00114] The organic layer was collected in a separate vessel. The reactor was washed with water (2 L), MeOH (2 L) and flushed with nitrogen gas. The wet solution of compound B was recharged into the reactor and (S)-propylene glycol ((S)-PG) (67.03 g, 0.872 mole) was introduced. Optionally, seed crystals of (S)-PG Ia can be added at this stage. Seed crystals can be prepared by dissolving compound I in a solvent such as MTBE and treating the resulting solution with (S)-propylene glycol and proceeding as described above without the use of seeding. [001151 Instantaneous crystallization produced a thick slurry. After stirring for 1 hour, cyclohexane (2.5 L) was added rapidly over 10 minutes and the stirring was continued for 21. hours. The product was filtered through a filter paper (Whatman #5, Buchner funnel 24" diameter). The filtration was rapid and took about 15 minutes. The filter cake was washed with a mixture (1:1) of MTBE/cyclohexane (2 x 1 L) and dried under suction for 0.5 hour. The solid was transferred to a pyrex tray and dried under vacuum (25 mm Hg) in an oven at 25-301C for two days till water analysis by K.F. corresponded to monohydrate (3.6 wt.%). The (S)-PG product Ia was obtained (0.425 kg, yield 97%) as a snow white solid, mp 71*C, HPLC AP 99.7. (HPLC method: Mobile Phase A: 0.05% TFA in H 2 0. Mobile Phase B: 0.05% TFA in CAN. Column: YMC Hydrosphere 4.6x150 (3p). Gradient: -39L 30-90%B over 45 minutes, hold 5 minutes; back to 30%B and re-equilibrate for 10 min. Wavelength: 220 rn. Injection Volume: I Ol. Temperature: Ambient). [001161 The (R) form of dapagliflozin can be prepared using these methods and substituting (S)-propylene glycol with (R)-propylene glycol. Example 2B: Preparation of dapagliflozin (S)-propylene glycol hydrate (compound Ia) [001171 The structure Ia can alternatively be prepared as described and depicted schematically below. Cl OEt -4.5 eq.OEt Ao NaOH (as 3N HO AoO solution) HO +4q. AO -OAc 'meh6 HO OH NaOAc Ac0N' "'OAc 70e7Theil' OAc _ OH Compound A CzH, 3 CiOI, Exact Mass: 576.18 Mol. Wt.: 577.02 C, 60.36; H, 5.76; Cl, 6.14; 0, 27.73 Cl OE 1) Neutralize to pH 6 -7.5 using 0 1N acetic meld HO 2)l Impoy acetate HO 'OH HO 3) (S)-(+).1.2 propanediol (1 eq.) H 4) Cyclohexane OH OH Ia CzHasCIO, Exact Mass: 502.20 Mol. WI.: 502.98 C, 57.31; H, 7.01; C1, 7.05; 0, 28.63 [001181 2 0g of compound A was charged to a reactor at ambient temperature and pressure. 30mL Methanol and 49.75mL 3N NaOH were added to the reactor and the reaction mixture was heated to 80*C or reflux, and held about 2-3 hours for reaction completion < 0.5 AP. The batch was cooled to 20'C and neutralized to pH 6.0-7.5 using IN acetic acid (requires ~I mL/gm input). 40 [00119] Extraction: The product was extracted from the reaction mixture into 1 00mL isopropyl acetate, the aqueous phase was split away and the organic phase washed with water until conductivity < 1 OmS (- 4mL/gm input). The aqueous phase was split away. [001201 Crystallization: 2.8g (1.05 eq) (S)-(+)-1,2 Propanediol 96%+ was added to the reaction mixture. The batch was seeded with 0.lg compound I seed. 160mL Cyclohexane was added and the batch cooled to 5"C. The batch was allowed to stir at 5"C at least I hour before isolation. [001211 Isolation and Drying: Each load of isolated cake was washed with 50/50 by volume isopropyl acetate/cyclohexane mixture. The cake was dried at 30"C in a vacuum oven under full vacuum. (Cake is dry when KF = 3.6% - 4.1%). Yield = 84% (uncorrected) Typical purity = 99.81 AP Typical PG content = 15.1 - 15.8% by GC [001221 Capsules containing the SGLT2 inhibitor of Formula I (dapagliflozin) or Formula la (dapagliflozin (S)- Propylene glycol hydrate) were prepared in strengths of 2.5 mg (Example 3), 10 mg (Example 4) and 100 mg (Example 5) as two-piece, gray opaque size #0 (2.5 mg and 10 mg) and size #00 (for 100 mg) hard gelatin capsules. Example 3 - Preparation of Dapagliflozin/Dapagliflozin propylene glycol hydrate Capsule, 2.5 mg [001231 A 25.0 mg of stock granulation was prepared containing 10% dapagliflozin or dapagliflozin propylene glycol hydrate filled in gray, opaque, size #0 capsule shell. A. Stock Granulation Composition Ingredient Amount (% w/w) 41- Dapagliflozin or Dapagliflozin propylene glycol hydrate 10.0 (Or equivalent amount of Dapagliflozin propylene glycol hydrate) Pregelatinized Starch 15.0 Microcrystalline Cellulose 68.75 Sodium Starch Glycolate 3.0 Silicon Dioxide 2.0 Magnesium Stearate 1.25 [00124] The amount of dapagliflozin is theoretically equivalent to 81.29% of dapagliflozin propylene glycol hydrate, either of which can be used. The actual amount of dapagliflozin propylene glycol hydrate will depend on the purity. The microcrystalline cellulose is the compensating excipient whose amount can vary depending on the actual amount of dapagliflozin propylene glycol hydrate and magnesium stearate used. The preferred amount of magnesium stearate is 1.25% (w/w). A useful range is 1.
2 5 -1.50% (w/w). [00125] The stock granulation of Part A and the Example 3 capsules were prepared according to the following procedures. 1001261 B. Example 3 Stock granulation procedure 1. Screen dapagliflozin or dapagliflozin propylene glycol hydrate. 2. Screen silicon dioxide. 3. Mix silicon dioxide with dapagliflozin or dapagliflozin propylene glycol hydrate in a suitable blender. 4. Screen pregelatinized starch and microcrystalline cellulose, if necessary. 5. Add ingredients from Step 4 to a suitable blender. 6. Add mixture from Step 3 to the blend from Step 5, and mix. 7. Screen sodium starch glycolate. 8. Add ingredient from Step 7 to the blend from Step 6, and mix. 9. Screen the blend from Step 8, and mix. 10. Screen portion of magnesium stearate. 11. Add ingredient from Step 10 to the blend from Step 9, and mix.
12. Densify the blend from Step 11. 13. Reduce the densified blend Step 12. 14. Screen the remaining portion of magnesium stearate. 15. Add ingredient from Step 14 to the granulation from Step 13, and mix. [001271 C. Example 3 Product: Dapagliflozin/Dapagliflozin propylene glycol hydrate Capsule, 2.5 mg 1. Fill empty capsule shells with sufficient Example 3 Part A stock granulation for capsules (10.0%) w/w (as the non-solvated form), to provide 2.5 mg capsules. 2. De-dust the capsules. Example 4 -Preparation of Dapagliflozin/Dapagliflozin propylene glycol hydrate Capsule, 10 mg [00128] A. Stock Granulation Composition Stock granulation composition was prepared as described in Example 3A. 1001291 B. Example 4 Stock granulation procedure Stock granulation procedure was performed as described in Example 3B. [001301 C. Example 4 Product: Dapagliflozin Capsule, 10 mg 1. Fill empty capsule shells with Example 3 Part A stock granulation Ibr capsules (10.0 % w/w as the non-solvated forn), to provide 10 mg capsules. 2. De-dust the capsules. 3. Weight sort the capsules. Example 5: Preparation of Dapagliflozin/Dapagliflozin propylene glycol hydrate Capsule, 100 mg 43- [00131] Composition: 438.6 ng of dapagliflozin (Example 5 Part A) Stock Granulation for Capsules (22.8% w/w), filled in Gray, Opaque, Size #0 Capsule Shell was prepared. A. Stock Granulation Composition Ingredient Amount (% w/w) Dapagliflozin or Dapagliflozin propylene glycol hydrate 22.8 (Or equivalent amount of Dapagliflozin propylene glycol hydrate) Pregelatinized Starch 15.0 Microcrystalline Cellulose 55.95 Sodium Starch Glycolate 3.0 Silicon Dioxide 2.0 Magnesium Stearate 1.25 [00132] The amount of dapagliflozin is theoretically equivalent to 81.29% of dapagliflozin propylene glycol hydrate hydrate, either of which can be used. The actual amount of dapagliflozin propylene glycol hydrate will depend on the purity. The microcrystalline cellulose is the compensating excipient whose amount can vary depending on the actual amount of dapagliflozin propylene glycol hydrate and magnesium stearate used. The preferred amount of magnesium stearate is 1.25% (w/w) A useful range is 1.25-1.50% (w/w). 100133] The stock granulation of Part 5A and the Example 5 capsules were prepared according to the following procedures.
[
0 0 134] R. Stock Granulation Procedure I. Screen silicon dioxide. 2. Mix silicon dioxide with dapagliflozin or dapagliflozin propylene glycol hydrate in a suitable blender. 3. Screen the blend from Step 2, and mix again. 4. Screen pregelatinized starch and microcrystalline cellulose, if necessary. 5. Add ingredients form Step 4 to the blend from Step 3, and mix. 44 6. Screen sodium starch glycolate. 7. Add ingredient from Step 6 to the blend from Step 5, and mix. 8. Screen a portion of magnesium stearate. 9. Add ingredient from Step 8 to the blend from Step 7, and mix. 10. Densify the blend from Step 9. 11. Reduce the densifled blend f'om Step 10. 12. Screen the remaining portion of magnesium stearate. 13. Add ingredient from Step 12 to the granulation from Step 11, and mix. 1001351 C. Example 5 Product: Dapagliflozin/Dapagliflozin propylene glycol hydrate Capsule, 100 mg 1. Fill empty capsule shells with Example 5 stock granulation for capsules (22.8 % w/w as the non-solvated forn). 2. De-dust the capsules. 3. Weight sort the capsules. [001361 The formed capsules of Example 3 (2.5 mg), Example 4 (10 mg), and Example 5 (100 mg) are used in treating metabolic disorders, including obesity. Example 6 -Treatment of Metabolic Disorders [001371 An oral solution (0.5 mg/mL) was prepared by dissolving dapagliflozin or dapagliflozin propylene glycol hydrate in a mixture of polyethylene glycol 400, NF and water (USP or purified water) 30:70% v/v. The oral solution was clear and colorless. 1001381 The glucosuric effects of dapagliflozin propylene glycol hydrate results in significant loss of calories in the urine versus a known SGLT2 inhibitor (GSK 869,682). The results of an indirect comparison of two single ascending dose studies of SGLT2 inhibitors is described. The amount of glucose excretion/day in healthy subjects taking 50, 100, 200 or 500 mg of GSK 869,682 was approximately 5g, 6g, l2g, and 16g, respectively. The amount of glucose excretion/day in healthy subjects taking 5, 20, 50 or 100 mg of dapagliflozin propylene glycol hydrate was 45 approximately 30g, 55g, 60g, and 70g, respectively. The results of the dapagliflozin propylene glycol hydrate study was further confirmed in a 14-day multiple ascending dose phase 2a study in subjects with type 2 diabetes. Patients with type 2 diabetes were treated with placebo, 5 mg dapagliflozin propylene glycol hydrate, 25 mg dapagliflozin propylene glycol hydrate, or 100 ing dapagliflozin propylene glycol hydrate. Results from the 24-hour glucose excretion show that subjects taking 5 mg, 25 mg, and 100mg dapagliflozin propylene glycol hydrate had significantly higher urine glucose excretion compared to subjects taking placebo. Diet-Induced Obesity in Rats 1001391 Obesity was induced in male Sprague-Dawley rats (mean baseline weight = 220 g) via ad libitum access to 2 diets: normal diet (Harlan Teklad rat chow; 3.5 kcal/gm, 5% vegetable fat) and high-sucrose/high-fat diet (Research Diets D12327; 4.6 kcal/gm, 40% sucrose and 40% vegetable fat). Rats under these conditions typically consume approximately 30 g/day of the high-sucrose/high-fat chow and 2 g/day of the normal Harlan Teklad rat chow. A 2 20-g rat given access to both diets wl1 weigh approximately 730 g after 10 weeks. Acute Glucosuria Study [00140] Dapagliflozin propylene glycol hydrate (1, 5, or 10 mg/kg ) or placebo (vehicle) was orally administered to diet-induced obese (DIO) rats after 24-hour baseline urine samples were collected. Urine volume and glucose concentration were used to determine total urine glucose loss over 24 hours post dose. [001411 Total urine glucose was determined after 24 hours administration of dapagliflozin propylene glycol hydrate. Total glucose lost was calculated as volume of urine x glucose concentration. The results showed that the total amount of glucose lost over 24 hours post dose was significantly increased with increasing doses of dapagliflozin propylene glycol hydrate in a dose-dependent manner. Chronic Weight Loss Study [001421 DIO rats were sorted into treatment groups based on body weight, total kilocalories consumed, and body composition (via echo MRI). Dapagliflozin propylene glycol hydrate (0.5, 1, or 5 mpk) or placebo was orally administered to 46 DIO rats for 28 days. To assess the importance of compensatory over-eating in drug-treated animals, a subgroup of rats that received 5 mg/kg of dapagliflozin propylene glycol hydrate was restricted to the food intake of the placebo group. Body weight and the weight of both diets were determined daily. Respiratory quotient data were obtained on days 2 and 15 of the study, echo MRI was obtained on day 22, and blood was collected for a fasting clinical chemistry tests on day 27. [00143] Chronically administered dapagliflozin propylene glycol hydrate (administered daily over 25 days) produced significant weight loss (p<.05 versus vehicle) in diet-induced obese rats. If the compound-induced overeating was prevented (dapaglitlozin propylene glycol hydrate mg/kg pair fed to vehicle group), then the weight loss was greater. Percent weight changes were calculated as daily weight - day 0 weight x 100. Weight Loss in Patients with Type 11 Diabetes [00144] Treatment naive type II diabetes mellitus patients, n=3 89, with inadequate blood glycemic control and low mean glucosuria at baseline were given once-daily oral treatments with dapagliflozin propylene glycol hydrate (2.5, 5, 10, 20, or 50 mgs), metformin XR* (750 mg titrated to 1500 mgs), or placebo over 12 weeks. [00145] Treatment with dapagliflozin propylene glycol hydrate resulted in consistent and sustained increases in urinary glucose excretion, rising to mean glucosuria values between 51.8 g/day to 85.0 g/day at week 12 from baseline means between 5.8 grams/day to 10.9 grams/day. Mean glucosuria with placebo and metformin both remained low, 5.7 grains/day and 5.6 grams/day respectively at week 12. A higher proportion of patients in each of the dapagliflozin propylene glycol hydrate groups achieved a 5% weight reduction over those patients taking placebo. Mean percent reductions for body weight and absolute changes in body mass index (BMI) over 12 weeks are shown in Table Ill. Table III Dapagliflozin-PGS Dose 2.5 mgs 5 mgs 10 mgs 20 mgs 50 mgs Placebo Metformin n=59 n=58 n=47 n=59 n=56 n=54 n=56 Baseline weight 90 89 86 88 91 89 88 (kg) Mean reduction -2.7 -2.5 -2.7 -3.4 -3.4 -1.2 -1.7 In weight (%)__ _ Baseline BMI 31 31 30 31 32 32 32 (kg/m 2 ) Mean reduction -0.9 -0.8 -0.8 -1.0 -1.1 -0.3 -0.5 i BMI Example 7 - Preparation of Dapagliflozin/Dapagliflozin Propylene glycol hydrate Tablet, 2.5 mg [001461 Tablets containing the SGLT2 inhibitor dapagliflozin or dapagliflozin propylene glycol hydrate were prepared in strengths of 2.5 mg (Example 7), 10 mg (Example 8) and 50 mg (Example 9) as described below. [001471 Product: Dapagliflozin/Dapagliflozin Propylene glycol hydrate Tablet, 2.5 mg A. Tablet Composition Ingredient Amount Dapagliflozin propylene glycol hydrate 3.08 mg (Or equivalent amount of Dapagliflozin) Microcrystalline Cellulose 67.11 ma Anhydrous Lactose 2 5 .00 mg Crospovidone 8.75 mg Croscarmellose Sodium 3.75 mg Talc 1 2 .50 mg Silicon Dioxide 2.88 ing Magnesium Stearate 1.94 mg 48 [001481 The amount of dapagliflozin is theoretically equivalent to 81.29% of dapagliflozin propylene glycol hydrate, either of which can be used. The actual amount of dapagliflozin propylene glycol hydrate will depend on the purity. The microcrystalline cellulose is the compensating excipient whose amount can vary depending on the actual amount of dapagliflozin propylene glycol hydrate and magnesium stearate used. The target amount of magnesium stearate is 1.94 mg. An acceptable range is about 1.55 to about 2.33 mg. 1001491 The stock granulation of Part 7A and the Example 7 tablets were prepared according to the following procedures. [00150] B. Stock Granulation Procedure I. Deaggregate dapagliflozin propylene glycol hydrate or dapagliflozin and magnesium stearate separately using a suitable screen. 2. Mix dapagliflozin propylene glycol hydrate or dapaglillozin with a portion of microcrystalline cellulose in a suitable mixer; pass through a mill; and transfer it into a suitable blender. 3. "Dry Rinse" the mixer used for mixing Step 2 with a portion of microcrystalline cellulose. 4. Add the blend from Step 3 to the blend from Step 2. 5. Mix the mixture from Step 4 with remaining microcrystalline cellulose, portion of crospovidone, portion of croscarmellose sodium, portion of silicon dioxide and Anhydrous Lactose. 6. Add talc and intragranular magnesium stearate to the mixture from Step 5 and mix. 7. Compact the powder blend from Step 6. 8. Reduce compact from Step 7 to form granules. 9. Mix the granules from Step 8 with remaining amounts of crospovidone, croscarmellose sodium and silicon dioxide. 10. Mix the granules from Step 9 with remaining amount of magnesium stearate. 49.
[001511 C. Example 7 Product: Dapagliflozin/Dapagliflozin propylene glycol hydrate Tablet, 2.5 mg 1. Setup the tabletting equipment. 2- Compress the Example 7 stock granulation into tablets. Example 8- Preparation of Dapagliflozin/Dapagliflozin propylene glycol hydrate Tablet, 10 mg [00152] Product: Dapagliflozin/Dapagliflozin propylene glycol hydrate Tablet, 10 mg A. Tablet Composition Ingredient Amount Dapagliflozin propylene glycol hydrate 12.30 mg (Or equivalent amount of Dapagliflozin) Microcrystalline Cellulose 57.89 mg Anhydrous Lactose 25.00 mg Crospovidone 8.75 mg Croscarmellose Sodium 3.75 mg Talc 12.50 mg Silicon Dioxide 2.88 mg Magnesium Stearate 1.94 mg 100153] The amount of dapagliflozin is theoretically equivalent to 81.29% of dapagliflozin propylene glycol hydrate, either of which can be used. The actual amount of dapagliflozin propylene glycol hydrate will depend on the purity. The microcrystalline cellulose is the compensating excipient whose amount can vary depending on the actual amount of dapagliflozin propylene glycol hydrate and magnesium stearate used. The target amount of magnesium stearate is 1.94 mg. An acceptable range is about 1.55 to about 2.33 mg. -50 [001541 The stock granulation of Part 8A and the Example 8 tablets were prepared according to the following procedures. [00155] B. Stock Granulation Procedure 1. Deaggregate dapagliflozin propylene glycol hydrate or dapagliflozin and magnesium stearate separately using a suitable screen. 2. Mix microcrystalline cellulose, dapagliflozin propylene glycol hydrate or dapagliflozin, portion of crospovidone, portion of croscarmellose sodium, portion of silicon dioxide and anhydrous lactose in a suitable blender. 3. Add talc and intragranular magnesium stearate to the mixture from Step 2 and mix in a suitable blender. 4. Compact the powder blend from Step 3. 5. Reduce compact from Step 4 to form granules. 6. Mix the granules from Step 5 with remaining amounts of crospovidone, croscarmellose sodium and silicon dioxide. 7. Mix the granules from Step 6 with remaining amount of magnesium stearate. [00156] C. Example 8- Product: Dapagliflozin/Dapagliflozin propylene glycol hydrate Tablet, 10 mg 1. Setup the tabletting equipment. 2. Compress the Example 8 stock granulation into tablets. Example 9- Preparation of Dapagliflozin/Dapagliflozin propylene glycol hydrate Tablet, 50 mg [001571 Product: Dapagliflozin/Dapagliflozin propylene glycol hydrate Tablet, 50 mg A. Tablet Composition Ingredient Amount Dapagliflozin propylene glycol hydrate 61.66 mg (Or equivalent amount of Dapagliflozin) Microcrystalline Cellulose i14.09 mg Anhydrous Lactose 62.60 mg Crospovidone 21.91 mg Croscarmellose Sodium 9.39 mg Talc 31.30 mg Silicon Dioxide 7.20 mg Magnesium Stearate 4.85 mg 1001581 The amount of dapagliflozin is theoretically equivalent to 81.29% of dap.agliflozin propylene glycol hydrate, either of which can be used. The actual amount of dapagliflozin propylene glycol hydrate will depend on the purity. The microcrystalline cellulose is the compensating excipient whose amount can vary depending on the actual amount of dapagliflozin propylene glycol hydrate and magnesium stearate used. The target amount of magnesium stearate is 4.85 mg. An acceptable range is about 3.76 to about 5.95 mg,. [001591 The stock granulation of Part 9A and the Example 9 tablets were prepared according to the following procedures. [001601 B. Stock Granulation Procedure 1. Mix dapagliflozin propylene glycol hydrate or dapagliflozin, microcrystalline cellulose, anhydrous lactose, crospovidone, croscarmellose sodium, talc and silicon dioxide in a suitable blender. 2. Pass the mixture from Step 1 through a suitable mill. 3. Determine the yield from Step 1 and calculate the amount of magnesium stearate required. 4. Mix the mixture from Step 2 in a suitable blender. 5. Mix the mixture from Step 4 with magnesium stearate. 6. Dry granulate the powder blend from Step 5. 7. Size the granulation from Step 6. 8. Determine the yield based on Step 7. 9. Mix the granules from Step 8 with remaining amount of crospovidone, croscarmellose sodium and silicon dioxide. -52 10. Mix the granules from Step 9 with remaining amount of magnesium stearate. [00161] C. Example 9 Product: Dapagliflozin/Dapagliflozin propylene glyeni hydrnte Taiblet, " mig 1. Setup the tabletting equipment. 2. Compress the Example 9 stock granulation into tablets. Example 10- Preparation of Dapagliflozin/Dapagliflozin propylene glycol hydrate Tablets (10-, 25-, and 40 mg) [001621 Product: Dapagliflozin/Dapagliflozin propylene glycol hydrate Tablets (10 mg, 25 mg, and 40 mg) A. Granulation composition (% w/w) Ingredient Formulation % w/w Dapagliflozin propylene glycol hydrate 9.84 (Or equivalent amount of Dapagliflozin) Microcrystalline Cellulose 63.91 Anhydrous Lactose 20 Crospovidone 4 Silicon Dioxide 1.5 Magnesium Stearate 0.75 [00163] B. Stock Granulation Procedure: 1. Mix dapagliflozin propylene glycol hydrate or dapagliflozinwith microcrystalline cellulose. 2. Pass the mixture from step I through a suitable mill. 3. Mix the blend from step 2 with microcrystalline cellulose, lactose anhydrous, crospovidone, and silicon dioxide. 4. Mix the blend from step 3 with magnesium stearate. -53- 5. Dry granulate the powder blend from Step 4. 6. Size the granulation from Step 5 using appropriate sieve(s). 7. Determine the yield based on step 6. 8. Mix the granules from Step 7 with remaining amount of crospovidone, and silicon dioxide. 9. Mix granules from step 8 with remaining amount of magnesium stearate. [00164] Tablets or capsules of various strengths (8 - 50mg) can be prepared using different weights of this granulation using tabletting procedure described above. 100165] Tabletting/capsule filling operations: Same as other formulations provided herein. [001661 Film coating: Hydroxypropylmethyl cellulose, titanium dioxide, polyethylene glycol, and colorant. Alternative filn coating: Polyvinyl alcohol (PVA), titanium dioxide, polyethylene glycol, talc, and coulranit. Example 11- Preparation of Dapagliflozin/Dapagliflozin propylene glycol hydrate Tablets (1, 2.5, 5, 10 mg) [001671 Product: Dapagliflozin/DapagUflozin propylene glycol hydrate Tablets 1, 2.5, 5, 10 mg A. Granulation composition Ingredient 1mg 2.5mg 5mg 10mg Tablet Tablet Tablet Tablet apagliflozin propylene glycol .23 mg 3.075 mg 6.15 mg 12.3 0 mg hydrate (Or equivalent amount of Dapagliflozin) 'Microcrystalline Cellulose 50-90 mg 6 0 -115 mg 60-115 mg 120-230 mng
---------
54 -54 Ingredient 1 mg 2.5 mg 5mg 10 mg Tablet Tablet Tablet jTablet Lactose 10-30 mg 12.5-38mg 12.5-38 25-75 mg [mg --- - --- Crospovidone 2-10 mg 2.5-13 mg 1 2 .5-13 mg 5-25 mg Silicon Dioxide 0.5-4 mg 0.6-5 mg 0.
6 -5 mg l-10 mg Magnesium Stearate 0.5-2.0 mg 0.6-2.5 mg _0.6-2.5 mg 1-5 mg Antioxidant and/or chelating agent 0-0.5 mg 0-0.6 mg 6mg 0-1.25 mg B. Stock granulation procedure 1. Mix dapagliflozin propylene glycol hydrate or dapagliflozin with incrocrystalline cellulose. 2. Pass the mixture from step 1 through a suitable mill. 3. Mix the blend from step 2 with microcrystalline cellulose, lactose anhydrous, crospovidone, silicon dioxide. 4. Mix the blend from step 3 with magnesium stearate. 5. Dry granulate the powder blend from Step 4. 6. Size the granulation from Step 5 using appropriate sieve(s). 7. Determine the yield based on step 6. 8. Mix the granules from Step 7 with remaining amount of crospovidone, and silicon dioxide. 9. Mix granules fi-om step 8 with remaining amount of magnesium stearate. [001681 Tablets or capsules of various strengths (1 - 20mg ) can be prepared using different weights of this granulation. [001691 Tabletting/capsule filling operations: Same as other formulations provided herein. [001701 Film coating: Polyvinyl alcohol (PVA), titanium dioxide, polyethylene glycol, talc, and colorant. The term "comprising" as used in this specification and claims means "consisting at least in part of'. When interpreting statements in this specification and claims which -55.
include "comprising", other features besides the features prefaced by this ternA in each statement can also be present. Related terms such as "comprise" and "comprised" are to be interpreted in similar manner. In this specification where reference has been made to patent specifications, other external documents, or other sources of information, this is generally for the purpose of providing a context for discussing the features of the invention. Unless specifically stated otherwise, reference to such external documents is not to be construed as an admission that such documents, or such sources of information, in any jurisdiction, are prior art, or form any part of the common general knowledge in the art. -56

Claims (9)

  1. 2. The formulation as defined in Claim 1 wherein -57 b) the bulking agent is present in an amount within the range of from about 10 to about 85% by weight of the stock granulation or of tablet or capsule fill; c) the binder is present in an amount within the range of from about 1 to about 10% by weight of the stock granulation or of tablet or capsule fill; d) the disintegrant is present in an amount within the range of from about 0.25% to about 10% by weight of the stock granulation or of tablet or capsule fill; e) the glidant and/or anti-adherent, if present, is present in an amount within the range of from about 1% to about 15% by weight of the stock granulation or of tablet or capsule fill; and f) the lubricant, if present, is present in an amount within the range of from about 0% to about 5% by weight of tablet of the stock granulation or capsule fill.
  2. 3. The formulation as defined in Claim 1 or Claim 2, wherein the bulking agent is microcrystalline cellulose and/or lactose, the binder is pregelatinized starch, the disintegrant is sodium starch glycolate, crospovidone, and/or croscarmellose sodium, the glidant and/or antiadherent is silicon dioxide and/or talc, and the lubricant is magnesium stearate.
  3. 4. The formulation as defined in Claim I in the form of a tablet or in the form of a capsule, the tablet or capsule comprising: a) the dapagliflozin propylene glycol hydrate, wherein the dapagliflozin propylene glycol hydrate is present in an amount within the range of from about 0.1% to about 30% by weight of tablet or capsule fill; b) bulking agents comprising anhydrous lactose and/or microcrystalline cellulose, wherein the total amount of bulking agent is present in an amount within the range of from about 10% to about 85% by weight of tablet or capsule fill, wherein the anhydrous lactose, if present, is present in an amount within the range of from about 20% to about 75% by weight of tablet or capsule fill, and wherein the microcrystalline -58. cellulose is present in an amount within the range of from about 20% to about 75% by weight of tablet or capsule fll; c) a binder comprising pregelatinized starch, wherein the pregelatinized starch is present in an amount within the range of from about 10% to about 75% by weight of tablet or capsule fill; d) disintegrants comprising croscamellose sodium, crospovidone, and/or sodium starch glycolate, wherein the total amount of disintegrant is present in an amount within the range of from about 0.25% to about 10% by weight of tablet or capsule fill, wherein the croscarmellose sodium, if present, is present in an amount within the range of from about 2% to about 10% by weight of tablet or capsule fill, wherein the crospovidone, if present, is present in an amount within the range of from about 4% to about 10% by weight of tablet or capsule fill, and wherein the sodium starch glycolate, if present, is present in an ainuuut within the range of from about 2% to about 10% by weight of tablet or capsule fill; e) one or more glidants and/or anti-adherents comprising talc and/or silicon dioxide, wherein the total amount of glidant and/or anti-adherent is present in an amount within the range of from about 1% to about 10% by weight of tablet or capsule fill; f) a lubricant comprising magnesium stearate, wherein the magnesium stearate is present in an amount within the range of from about 0.2% to about 2% by weight of tablet or capsule fill; and g) optionally further comprising an outer protective coating layer comprising a coating polymer and optionally comprising one or more of the following: a plasticizer(s), anti-tacking agent(s), glidant(s), and colorant(s), wherein the total amount of the outer protective coating layer is present in an amount within the range of from about 1% to about 5% by weight of tablet or capsule fill.
  4. 5. The formulation as defined in Claim 1 in the form of a capsule filled with the stock granulation the capsule containing an amount of the dapagliflozin propylene glycol hydrate that is equivalent to 2.5 mg or 10 mg dapagliflozin, the stock granulation comprising: a) the dapagliflozin propylene glycol hydrate, wherein the dapagliflozin propylene glycol hydrate is present in an amount of 10% by weight of capsule fill; b) microcrystalline cellulose, wherein the microcrystalline cellulose is present in an amount of 68.75% by weight of capsule fill; c) pregelatinized starch, wherein the pregelatinized starch is present in an amount of 15% by weight of capsule fill; d) sodium starch glycolate, wherein the sodium starch glycolate is present in an amount of 3% by weight of capsule fill; e) silicon dioxide, wherein the silicon dioxide is present in an amount of 2% by weight of capsule fill; and f) magnesium stearate, wherein the magnesium stearate is present in an amount of 1.25% by weight of capsule fill.
  5. 6. The formulation as defined in Claim I in the form of a capsule filled the stock granulation, the capsule containing an amount of the dapagliflozin propylene glycol hydrate that is equivalent to 100 mg dapagliflozin, the stock aranulation comprising: a) the dapagliflozin propylene glycol hydrate, wherein the dapagliflozin propylene glycol hydrate is present in an amount of 22.8% by weight of capsule fill; b) microcrystalline cellulose, wherein the microcrystalline cellulose is present in an amount of 55.95% by weight of capsule fill; c) pregelatinized starch, wherein the pregelatinized starch is present in an amount of 15% by weight of capsule fill; d) sodium starch glycolate, wherein the sodium starch glycolate is present in an amount of 3% by weight of capsule fill; e) silicon dioxide, wherein the silicon dioxide is present in an amount of 2% by weight of capsule fill; and f) magnesium stearate, wherein the magnesium stearate is present in an amount of 1.25% by weight of capsule fill.
  6. 7. The formulation as defined in Claim I in the form of a tablet comprising: a) the dapagliflozin propylene glycol hydrate, wherein the dapagliflozin propylene glycol hydrate is present in an amount of 3.08 mg; -60 b) microciystalline cellulose, wherein the microcrystalline cellulose is present in an amount of 67.11 mg; c) anhydrous lactose, wherein the anhydrous lactose is present in an amount of25 mg; d) crospovidone, wherein the crospovidone is present in an amount of
  7. 8.75 mg; e) croscarmellose sodium, wherein the croscarmellose sodium is present in an amount of 3.75 mg; f) talc, wherein the talc is present in an amount of 12.5 mg; g) silicon dioxide, wherein the silicon dioxide is present in an amount of 2.88 mg; and h) magnesium stearate, wherein the magnesium stearate is present in an amount of 1.94 mg. 8. The formulation as defined in Claim I in the form of a tablet comprising: a) dapagliflozin propylene glycol hydrate, wherein the dapagliflozin propylene glycol hydrate is present in an amount of 12.3 mg; b) microcrystalline cellulose, wherein the microcrystalline cellulose is present in an amount of 57.89 mg; c) anhydrous lactose, wherein the anhydrous lactose is present in an amount of 25 mg; d) crospovidone, wherein the crospovidone is present in an amount of 8.75 mg; e) croscarmellose sodium, wherein the croscarmellose sodium is present in an amount of 3.75 mg; f) talc, wherein the talc is present in an amount of 12.5 mg; g) silicon dioxide, wherein the silicon dioxide is present in an amount of 2.88 mg; and h) magnesium stearate, wherein the magnesium stearate is present in an amount of 1.94 mg.
  8. 9. The formulation as defined in Claim I in the form of a tablet comprising: ,61- a) dapagliflozin propylene glycol hydrate, wherein the dapagliflozin propylene glycol hydrate is present in an amount of 61.66 mg; b) microcrystalline cellulose, wherein the microcrystalline cellulose is present in an amount of 114.09 ng; c) anhydrous lactose, wherein the anhydrous lactose is present in an amount of 62.6 mg; d) crospovidone, wherein the crospovidone is present in an amount of
  9. 21.91 mg; e) croscarmellose sodium, wherein the croscarmellose sodium is present in an amount of 9.39 mg; f) talc, wherein the talc is present in an amount of 31.3 mg; g) silicon dioxide, wherein the silicon dioxide is present in an amount of 7.2 mg; and h1) agnesiui stearate, wherein the magnesium stearate is present in an amount of 4.85 mng. 10. The formulation as defined in Claim 1, wherein said formulation is in the form of a tablet comprising: a) the dapagliflozin propylene glycol hydrate in an amount of 1.23 mg; b) microcrystalline cellulose, wherein the microcrystalline cellulose is present in an amount of about 50 mg to about 90 mg; c) lactose, wherein the lactose is present in an amount of about 10 mg to about 3 0 mg; d) crospovidone, wherein the crospovidone is present in an amount of about 2 tmg to about 10 mg; e) silicon dioxide, wherein the silicon dioxide is present in an amount of about 0.5 mg to about 4.0 mg; f) magnesium stearate, wherein the magnesium stearate is present in an amount of about 0.5 mg to about 2.0 mg; and g) an antioxidant and/or chelating agent, wherein the antioxidant and/or chelating agent is present in an amount of about 0 mg to about 0.5 mg. 11. The formulation as defined in Claim 1, wherein said formulation is in the form of a tablet comprising: a) the dapagliflozin propylene glycol hydrate in an amount of 3 .075mg; b) microcrystalline cellulose, wherein the microcrystalline cellulose is present in an amount of about 60 mg to about 15 mg; c) lactose, wherein the lactose is present in an amount of about 12.5 mg to about 38 rng; d) crospovidone, wherein the crospovidone is present in an amount of about 2.5 mg to about 13 mg; e) silicon dioxide, wherein the silicon dioxide is present in an amount of about 0.6 mg to about 5.0 mg; f) magnesium stearate. wherein the magnesium stearate is present in an amount of about 0.6 mg to about 2.5 mg; and g) an antioxidant and/or chelating agent, wherein the antioxidant and/or chelating agent is present in an amount of about 0 mg to about 0.6 mg. 12. The formulation as defined in Claim 3, wherein said formulation is in the form of a tablet comprising: a) the dapagliflozin propylene glycol hydrate in an amount of 6.15 mg; b) microcrystalline cellulose, wherein the microcrystalline cellulose is present in an amount of about 60 mg to ahont 1 15 mg; c) lactose, wherein the lactose is present in an amount of about 12.5 ng to about 38 mg; d) crospovidone, wherein the crospovidone is present in an amount of about 2.5 mg to about 13 mg; e) silicon dioxide, wherein the silicon dioxide is present in an amount of about 0.6 mg to about 5.0 mg; f) magnesium stearate, wherein the magnesium stearate is present in an amount of about 0.6 mg to about 2.5 mg; and g) an antioxidant and/or chelating agent, wherein the antioxidant and/or chelating agent is present in an amount of about 0 mg to about 0.6 mg. .6 31 13. The formulation as defined in Claim 1, wherein said formulation is in the forr of a tablet comprising: a) the dapagliflozin propylene glycol hydrate in an amount of 12.3 mg; b) microcrystalline cellulose, wherein the microcrystalline cellulose is present in an amount of about 120 mg to about 230 mg; c) lactose, wherein the lactose is present in an amount of about 25 mg to about 75 mg; d) crospovidone, wherein the crospovidone is present in an amount of about 5 mg to about 25 mg; e) silicon dioxide, wherein the silicon dioxide is present in an amount of about 1.0 mg to about 10 mg; f) magnesium stearate, wherein the magnesium stearate is present in an amount of about 1.0 mg to about 5 mg; and g) an antioxidant and/or chelating agent, wherein. the antioxidant and/or chelating agent is present in an amount of about 0 mg to about 1.25 mg. 14. A formulation as defined in any of Claims 1-4 and 10-13, further comprising one or more therapeutic agents selected from the group consisting of anti-diabetic agents, anti-hyperglycemic agents, hypolipidemic/lipid lowering agents; anti-obesity agents; anti-hypertensive agents and appetite suppressants. 15. A formulation as defined in any of Claims 1-4 and 10-13, further comprising saxagliptin. 16. A formulation as defined in any of Claims 1-4 and 10-13, further comprising metformin. 17. Use of the pharmaceutical formulation of any of claims 1-16 in the manufacture of a medicament for treating or delaying the progression or onset of Type I and Typ . .. II diabetes, impaired glucose tolerance, insulin resistance, nephropathy, retinopathy, neuropathy, cataracts, hyperglycemia, hyperinsulinemia, hypercholesterolemia, dyslipidemia, elevated blood levels of free fatty acids or glycerol, hyperlipidenia, -64 hypertriglyceridemia, obesity, wound healing, tissue ischemia, atherosclerosis, hypertension, or Syndrome X (Metabolic Syndrome) 18. Use of the pharmaceutical formulation of any of claims 1-16 in the manufacture of a medicament for treating or delaying the progression or onset of type II diabetes. .65
AU2008228714A 2007-03-22 2008-03-21 Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate Active AU2008228714B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014201239A AU2014201239B2 (en) 2007-03-22 2014-03-06 Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89628607P 2007-03-22 2007-03-22
US60/896,286 2007-03-22
PCT/US2008/057888 WO2008116179A1 (en) 2007-03-22 2008-03-21 Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014201239A Division AU2014201239B2 (en) 2007-03-22 2014-03-06 Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate

Publications (2)

Publication Number Publication Date
AU2008228714A1 AU2008228714A1 (en) 2008-09-25
AU2008228714B2 true AU2008228714B2 (en) 2013-12-19

Family

ID=39671801

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008228714A Active AU2008228714B2 (en) 2007-03-22 2008-03-21 Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate

Country Status (28)

Country Link
US (5) US7851502B2 (en)
EP (3) EP2139494B1 (en)
JP (2) JP5475636B2 (en)
KR (5) KR101532188B1 (en)
CN (2) CN102743340B (en)
AR (1) AR065809A1 (en)
AU (1) AU2008228714B2 (en)
BR (2) BR122017015098B8 (en)
CA (2) CA2929811C (en)
CL (1) CL2008000823A1 (en)
CY (3) CY1123143T1 (en)
DK (2) DK2139494T3 (en)
EA (2) EA027769B1 (en)
ES (2) ES2950089T3 (en)
FI (1) FI2508188T3 (en)
FR (1) FR20C1042I1 (en)
HK (1) HK1176004A1 (en)
HR (2) HRP20230691T1 (en)
HU (3) HUE048897T2 (en)
LT (3) LT2508188T (en)
MX (3) MX2009010155A (en)
PE (1) PE20090185A1 (en)
PL (2) PL2508188T3 (en)
PT (2) PT2508188T (en)
RS (1) RS60258B1 (en)
SI (2) SI2139494T1 (en)
TW (1) TW200904405A (en)
WO (1) WO2008116179A1 (en)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA91546C2 (en) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Crystalline form of 1-chloro-4-(я-d-glucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
TW200726755A (en) * 2005-07-07 2007-07-16 Astellas Pharma Inc A crystalline choline salt of an azulene derivative
PE20080697A1 (en) * 2006-05-03 2008-08-05 Boehringer Ingelheim Int BENZONITRILE DERIVATIVES SUBSTITUTED WITH GLUCOPYRANOSIL, PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS OF THIS TYPE, THEIR USE AND PROCEDURE FOR THEIR MANUFACTURE
CN101568537A (en) 2006-12-21 2009-10-28 安斯泰来制药有限公司 Method for producing C-glycoside derivative and synthetic intermediate thereof
TW200904405A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
TW200904454A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
CL2008002427A1 (en) * 2007-08-16 2009-09-11 Boehringer Ingelheim Int Pharmaceutical composition comprising 1-chloro-4- (bd-glucopyranos-1-yl) -2- [4 - ((s) -tetrahydrofuran-3-yloxy) benzyl] -benzene combined with 1 - [(4-methylquinazolin- 2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (r) -aminopiperidin-1-yl) xanthine; and its use to treat type 2 diabetes mellitus.
JP5596545B2 (en) * 2007-09-10 2014-09-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Method for producing a compound useful as an inhibitor of SGLT
EP2236137B1 (en) * 2008-01-31 2015-06-24 Astellas Pharma Inc. Pharmaceutical composition for treatment of fatty liver diseases
CA2725047A1 (en) * 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
AU2009270936B2 (en) 2008-07-15 2014-12-18 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
WO2010045656A2 (en) * 2008-10-17 2010-04-22 Nectid, Inc. Novel sglt2 inhibitor dosage forms
EP2395983B1 (en) 2009-02-13 2020-04-08 Boehringer Ingelheim International GmbH Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
JP5600328B2 (en) * 2009-02-13 2014-10-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pharmaceutical compositions comprising glucopyranosyldiphenylmethane derivatives, pharmaceutical dosage forms thereof, methods for their preparation and their use for improving glycemic control in patients
WO2010138535A1 (en) * 2009-05-27 2010-12-02 Bristol-Myers Squibb Company Methods for treating type 2 diabetes in patients resistant to previous treatment with other anti-diabetic drugs employing an sglt2 inhibitor and compositions thereof
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
EP2451797B1 (en) 2009-07-10 2013-04-03 Janssen Pharmaceutica, N.V. CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE
KR101813025B1 (en) 2009-09-30 2017-12-28 베링거 인겔하임 인터내셔날 게엠베하 Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
MX2012002942A (en) 2009-09-30 2012-04-11 Boehringer Ingelheim Int Method for the preparation of a crystalline form of 1-chloro-4- (beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)be nzyl)benzene.
US10610489B2 (en) * 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US9174971B2 (en) * 2009-10-14 2015-11-03 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
AU2014218385B2 (en) * 2009-11-13 2016-02-25 Astrazeneca Ab Bilayer tablet formulations
LT2498758T (en) 2009-11-13 2018-11-26 Astrazeneca Ab Bilayer tablet formulations
PL2498759T3 (en) 2009-11-13 2019-03-29 Astrazeneca Ab Immediate release tablet formulations
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
EP2368552A1 (en) * 2010-03-25 2011-09-28 Boehringer Ingelheim Vetmedica GmbH 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal
US20140088027A1 (en) * 2010-03-30 2014-03-27 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
WO2011142478A1 (en) * 2010-05-11 2011-11-17 Mitsubishi Tanabe Pharma Corporation Canagliflozin containing tablets
KR101931209B1 (en) 2010-05-11 2018-12-20 얀센 파마슈티카 엔.브이. Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienyl-methylbenzene derivatives as inhibitors of sglt
EP2582709B1 (en) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TWI541030B (en) * 2010-07-06 2016-07-11 健生藥品公司 Formulation for co-therapy treatment of diabetes
WO2012005340A1 (en) * 2010-07-07 2012-01-12 日本たばこ産業株式会社 Tablet containing ferric citrate
KR20130137624A (en) 2010-09-03 2013-12-17 브리스톨-마이어스 스큅 컴퍼니 Drug formulations using water soluble antioxidants
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TWI631963B (en) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2
BR112013019026A2 (en) * 2011-02-01 2016-10-04 Astrazeneca Uk Ltd pharmaceutical formulations including an amine compound
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
AR085689A1 (en) 2011-03-07 2013-10-23 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS OF METFORMIN, LINAGLIPTINE AND AN SGLT-2 INHIBITOR
AU2012241897C1 (en) 2011-04-13 2017-05-11 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
TWI542596B (en) 2011-05-09 2016-07-21 健生藥品公司 L-proline and citric acid co-crystals of (2s,3r,4r,5s,6r)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
MX2013014135A (en) 2011-06-03 2014-01-23 Boehringer Ingelheim Int Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents.
ES2448398T3 (en) 2011-06-03 2014-03-13 Ratiopharm Gmbh Pharmaceutical composition comprising dapagliflozin and cyclodextrin
WO2012163546A1 (en) 2011-06-03 2012-12-06 Ratiopharm Gmbh Pharmaceutical composition comprising dapagliflozin and cyclodextrin
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3763374A1 (en) * 2011-10-17 2021-01-13 Lexicon Pharmaceuticals, Inc. Solid dosage forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate
EP2597090A1 (en) * 2011-11-28 2013-05-29 Sandoz AG Crystalline dapagliflozin hydrate
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9145434B2 (en) 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
US9320727B2 (en) * 2012-08-30 2016-04-26 Taisho Pharmaceutical Co., Ltd Combinations of SGLT 2 inhibitors and antihypertensive drugs
HUE051406T2 (en) 2012-11-14 2021-03-01 Grace W R & Co Compositions containing a biologically active material and a non-ordered inorganic oxide
EP2968375B1 (en) 2013-03-14 2019-06-12 MSD International GmbH Methods for preparing sglt2 inhibitors
DK2981269T3 (en) 2013-04-04 2023-10-23 Boehringer Ingelheim Vetmedica Gmbh TREATMENT OF METABOLISM DISORDERS IN HORSES
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HUE041709T2 (en) 2013-04-05 2019-05-28 Boehringer Ingelheim Int Therapeutic uses of empagliflozin
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ES2906115T3 (en) 2013-04-18 2022-04-13 Boehringer Ingelheim Int Pharmaceutical composition, treatment methods and uses thereof
WO2014178040A1 (en) 2013-04-29 2014-11-06 Mapi Pharma Ltd. Co-crystals of dapagliflozin
TR201905586T4 (en) * 2013-07-22 2019-05-21 Sandoz Ag FORMULATIONS CONTAINING AMORF DAPAGLIFLOZINE
KR20240017116A (en) * 2013-12-17 2024-02-06 베링거잉겔하임베트메디카게엠베하 Treatment of metabolic disorders in feline animals
BR112016013164B1 (en) * 2013-12-27 2022-07-26 Chugai Seiyaku Kabushiki Kaisha SOLID PREPARATIONS CONTAINING TOFOGLYPHOZIN AND PROCESSES FOR PRODUCING THE SAME
WO2015104658A2 (en) * 2014-01-08 2015-07-16 Dr. Reddy’S Laboratories Limited Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
ES2951127T3 (en) 2014-01-23 2023-10-18 Boehringer Ingelheim Vetmedica Gmbh SGLT2 inhibitors for the treatment of metabolic disorders in canine animals
US20170056365A1 (en) 2014-02-28 2017-03-02 Sun Pharmaceutical Industries Limited Dapagliflozin compositions
US10688116B2 (en) 2014-04-01 2020-06-23 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals
KR20160013770A (en) * 2014-07-28 2016-02-05 한미정밀화학주식회사 Novel crystalline complex of dapagliflozin and method for preparing same
US10555958B2 (en) 2014-09-25 2020-02-11 Boehringer Ingelheim Vetmedica Gmbh Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
WO2016055945A1 (en) * 2014-10-08 2016-04-14 Dr. Reddy’S Laboratories Limited Polymorphs of canagliflozin
CN104496952B (en) * 2014-11-28 2017-04-19 深圳翰宇药业股份有限公司 Synthesis method of dapagliflozin
AU2016310535B2 (en) 2015-08-27 2021-08-19 Boehringer Ingelheim Vetmedica Gmbh Liquid pharmaceutical compositions comprising SGLT-2 inhibitors
US20170071970A1 (en) * 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN105853386B (en) * 2016-04-01 2020-01-07 北京凯莱天成医药科技有限公司 Tablet containing dapagliflozin propylene glycol hydrate and preparation method thereof
WO2017203229A1 (en) * 2016-05-27 2017-11-30 Cipla Limited Dapagliflozin premixes
WO2018043463A1 (en) 2016-08-30 2018-03-08 国立大学法人新潟大学 Drug for removing aged cells
AU2017344882A1 (en) 2016-10-19 2019-03-28 Boehringer Ingelheim International Gmbh Combinations comprising an SSAO/VAP-1 inhibitor and a SGLT2 inhibitor, uses thereof
WO2018167589A1 (en) 2017-03-16 2018-09-20 Inventia Healthcare Private Limited Pharmaceutical composition comprising dapagliflozin
SG10201913562VA (en) * 2017-04-24 2020-03-30 Samus Therapeutics Inc Hsp90 inhibitor oral formulations and related methods
US20230190714A1 (en) * 2017-05-11 2023-06-22 Richard Postrel Primary methods and processes for life extension in modern-day humans
TWI797133B (en) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 Solid compositions for oral administration
KR102025480B1 (en) 2017-12-12 2019-09-25 영남대학교 산학협력단 Pharmaceutical Formulations of Dapagliflozin Free Base and Method for Preparing thereof
WO2019162841A1 (en) * 2018-02-21 2019-08-29 Glenmark Pharmaceuticals Limited Pharmaceutical composition comprising remogliflozin for treatment of diabetes mellitus
WO2019201752A1 (en) 2018-04-17 2019-10-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN112955966A (en) 2018-06-14 2021-06-11 阿斯利康(英国)有限公司 Method for lowering blood glucose using gliflozin Sodium (gliflozin Sodium) -glucose co-transporter 2 inhibitor pharmaceutical composition
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
US11346786B2 (en) * 2018-10-09 2022-05-31 Sensor International, Llc High pressure sensitive color changeable indicators and methods of making such indicators
US11033544B2 (en) * 2019-03-25 2021-06-15 The George Institute for Global Health Low-dose triple combination formulation
KR102234154B1 (en) 2019-06-18 2021-03-31 삼천당제약주식회사 Preparation method of tablet containing dapagliflozin ansolvate and tablet containing dapagliflozin ansolvate prepared by the same
AU2020202887B2 (en) * 2019-08-30 2021-05-20 Astrazeneca Ab Methods of treating heart failure with reduced ejection fraction with dapagliflozin
US11759474B2 (en) 2019-11-28 2023-09-19 Boehringer Ingelheim Vetmedica Gmbh Use of SGLT-2 inhibitors in the drying-off of non-human mammals
CA3167531A1 (en) 2020-02-17 2021-08-26 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
WO2021165316A1 (en) 2020-02-21 2021-08-26 Zakłady Farmaceutyczne POLPHARMA S.A. Pharmaceutical composition comprising dapagliflozin
WO2021176096A1 (en) 2020-03-05 2021-09-10 Krka, D.D., Novo Mesto Pharmaceutical composition comprising sglt2 inhibitor
CN115916197A (en) 2020-04-22 2023-04-04 拜耳公司 Combination of non-neferone and SGLT2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
CN115867538A (en) 2020-06-05 2023-03-28 新梅斯托克公司 Preparation of highly pure amorphous dapagliflozin
TR202019592A2 (en) 2020-12-03 2022-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Solid pharmaceutical formulations of amorphous dapagliflozin
EP4315350A1 (en) 2021-04-01 2024-02-07 AstraZeneca UK Limited Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
KR20240040106A (en) 2021-07-28 2024-03-27 베링거잉겔하임베트메디카게엠베하 Use of SGLT-2 inhibitors for the prevention and/or treatment of kidney disease in non-human mammals
WO2023006745A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
CN117715640A (en) 2021-07-28 2024-03-15 勃林格殷格翰动物保健有限公司 Use of SGLT-2 inhibitors for preventing and/or treating heart diseases in non-human mammals excluding felines, particularly canines
CN113648304A (en) * 2021-09-06 2021-11-16 扬子江药业集团上海海尼药业有限公司 Pharmaceutical composition containing dapagliflozin and preparation method and application thereof
KR20230084974A (en) 2021-12-06 2023-06-13 에이치케이이노엔 주식회사 Wet granulation composition comprising Dapagliflozin propanediol hydrate, granules, tablets, methods for their preparation, and granules or tablets prepared by the method
WO2023129595A1 (en) 2021-12-30 2023-07-06 Newamsterdam Pharma B.V. Obicetrapib and sglt2 inhibitor combination
WO2023144722A1 (en) * 2022-01-26 2023-08-03 Astrazeneca Ab Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
WO2023227492A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
KR102490653B1 (en) 2022-08-03 2023-01-20 진양제약주식회사 Pharmaceutical composition comprising dapagliflozin and glimepiride

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099836A1 (en) * 2002-05-20 2003-12-04 Bristol-Myers Squibb Company C-aryl glucoside sglt2 inhibitors and method
WO2008002824A1 (en) * 2006-06-28 2008-01-03 Bristol-Myers Squibb Company Crystalline solvates and complexes of (is) -1, 5-anhydro-l-c- (3- ( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4027009A (en) 1973-06-11 1977-05-31 Merck & Co., Inc. Compositions and methods for depressing blood serum cholesterol
US3970651A (en) 1974-01-07 1976-07-20 Bristol-Myers Company Crystalline cephalosporin derivative
JPS5612114B2 (en) 1974-06-07 1981-03-18
JPS5495589A (en) 1977-12-30 1979-07-28 Sumitomo Chem Co Ltd Production of cephalosporin derivative
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
DK149080C (en) 1980-06-06 1986-07-28 Sankyo Co METHOD FOR PREPARING ML-236B CARBOXYLIC ACID DERIVATIVES
US4450171A (en) 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4448784A (en) 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4499289A (en) 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
CA1327360C (en) 1983-11-14 1994-03-01 William F. Hoffman Oxo-analogs of mevinolin-like antihypercholesterolemic agents
US4613610A (en) 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4686237A (en) 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
KR910003427B1 (en) 1984-12-04 1991-05-31 산도즈 파마슈티칼스 코포레이션 Process for preparing indene analogs of mevalonolactone and derivatives thereof
US4668794A (en) 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
HUT48208A (en) 1985-10-25 1989-05-29 Sandoz Ag Process for producing heterocyclic analogues of mevalolactone derivatives and pharmaceutical compositions comprising such compounds
FR2596393B1 (en) 1986-04-01 1988-06-03 Sanofi Sa HYDROXY-3 DIHYDROXYOXOPHOSPHORIO-4 BUTANOIC ACID DERIVATIVES, THEIR PREPARATION PROCESS, THEIR USE AS MEDICAMENTS AND THE COMPOSITIONS CONTAINING THEM
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
SE503210C2 (en) 1987-05-22 1996-04-22 Squibb & Sons Inc Phosphorus-containing HMG-CoA-Reductase Inhibitor, New Intermediates and Methods
US4759923A (en) 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
JP2569746B2 (en) 1987-08-20 1997-01-08 日産化学工業株式会社 Quinoline mevalonolactones
US4871721A (en) 1988-01-11 1989-10-03 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors
US4924024A (en) 1988-01-11 1990-05-08 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
NO177005C (en) 1988-01-20 1995-07-05 Bayer Ag Analogous process for the preparation of substituted pyridines, as well as intermediates for use in the preparation
US5506219A (en) 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
US5753675A (en) 1989-03-03 1998-05-19 Novartis Pharmaceuticals Corporation Quinoline analogs of mevalonolactone and derivatives thereof
FI94339C (en) 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
JP2648897B2 (en) 1991-07-01 1997-09-03 塩野義製薬株式会社 Pyrimidine derivatives
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5470845A (en) 1992-10-28 1995-11-28 Bristol-Myers Squibb Company Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia
US5594016A (en) 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
CA2150372C (en) 1993-01-19 2002-08-20 Nancy L. Mills Stable oral ci-981 formulation and process of preparing same
US5340583A (en) 1993-05-06 1994-08-23 Allergan, Inc. Antimicrobial lenses and lens care systems
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5488064A (en) 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5385929A (en) 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5491134A (en) 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
DE69636677D1 (en) 1995-12-13 2006-12-14 Univ California Crystals of ligand complexed ligand binding domain of the thyroid hormone receptor
US5770615A (en) 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5962440A (en) 1996-05-09 1999-10-05 Bristol-Myers Squibb Company Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5885983A (en) 1996-05-10 1999-03-23 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB9713739D0 (en) 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
CA2819705C (en) 1998-02-02 2014-07-08 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
AU3034299A (en) 1998-03-09 1999-09-27 Fondatech Benelux N.V. Serine peptidase modulators
DE19823831A1 (en) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim New pharmaceutical use of isoleucyl thiazolidide and its salts
DE19828114A1 (en) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs of unstable inhibitors of dipeptidyl peptidase IV
DE19828113A1 (en) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs of Dipeptidyl Peptidase IV Inhibitors
SK18822000A3 (en) 1998-07-06 2001-12-03 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
NZ520024A (en) * 2000-02-29 2005-03-24 Bristol Myers Squibb Co Low dose entecavir formulation and usein treating hepatitis B virus infection
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AU2002254567B2 (en) 2001-04-11 2007-10-11 Bristol-Myers Squibb Company Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
KR100431431B1 (en) 2001-04-25 2004-05-14 한미약품 주식회사 Clathrate of azithromycin hydrate with 1,2-propyleneglycol, methods for the manufacture thereof, and pharmaceutical compositions thereof
EP1572892A4 (en) 2001-10-18 2007-08-22 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2004060347A2 (en) 2002-09-03 2004-07-22 Transform Pharmaceuticals, Inc. Pharmaceutical propylene glycol solvate compositions
WO2004061433A1 (en) * 2002-12-30 2004-07-22 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
EP1511490A4 (en) * 2002-05-31 2009-03-11 Transform Pharmaceuticals Inc Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
CA2512389A1 (en) 2003-01-03 2004-07-29 Bristol-Myers Squibb Company Methods of producing c-aryl glucoside sglt2 inhibitors
WO2004076470A2 (en) 2003-02-27 2004-09-10 Bristol-Myers Squibb Company A non-cryogenic process for forming glycosides
TWI415635B (en) 2004-05-28 2013-11-21 必治妥施貴寶公司 Coated tablet formulation and method
AR051446A1 (en) 2004-09-23 2007-01-17 Bristol Myers Squibb Co C-ARYL GLUCOSIDS AS SELECTIVE INHIBITORS OF GLUCOSE CONVEYORS (SGLT2)
CA2588963C (en) 2004-11-18 2013-06-25 Kissei Pharmaceutical Co., Ltd. 1-substituted-3-.beta.-d-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same
TW200904405A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
KR101483259B1 (en) 2012-08-28 2015-01-14 주식회사 아모센스 Non-shrinkage varistor substrate and method for manufacturing the same
WO2014178040A1 (en) 2013-04-29 2014-11-06 Mapi Pharma Ltd. Co-crystals of dapagliflozin
CN104829572B (en) 2014-02-10 2019-01-04 江苏豪森药业集团有限公司 Dapagliflozin novel crystal forms and preparation method thereof
JP6575470B2 (en) 2016-09-07 2019-09-18 トヨタ自動車株式会社 Traveling device

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099836A1 (en) * 2002-05-20 2003-12-04 Bristol-Myers Squibb Company C-aryl glucoside sglt2 inhibitors and method
WO2008002824A1 (en) * 2006-06-28 2008-01-03 Bristol-Myers Squibb Company Crystalline solvates and complexes of (is) -1, 5-anhydro-l-c- (3- ( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes

Also Published As

Publication number Publication date
LT2508188T (en) 2023-07-25
TW200904405A (en) 2009-02-01
PT2139494T (en) 2020-05-19
PL2508188T3 (en) 2023-09-11
US20120263786A1 (en) 2012-10-18
CY1126112T1 (en) 2023-11-15
EA201490477A1 (en) 2014-06-30
SI2139494T1 (en) 2020-07-31
EA027769B1 (en) 2017-08-31
BRPI0809233A2 (en) 2014-09-02
KR101502292B1 (en) 2015-03-12
EP2139494B1 (en) 2020-03-11
ES2950089T3 (en) 2023-10-05
KR20150038555A (en) 2015-04-08
MX352480B (en) 2017-11-27
JP5813147B2 (en) 2015-11-17
BR122017015098B1 (en) 2018-05-15
US9198925B2 (en) 2015-12-01
PE20090185A1 (en) 2009-02-28
KR20140124874A (en) 2014-10-27
US8716251B2 (en) 2014-05-06
JP2010522244A (en) 2010-07-01
FI2508188T3 (en) 2023-07-19
CA2929811C (en) 2019-04-16
HUE062284T2 (en) 2023-10-28
US20110064801A1 (en) 2011-03-17
CA2681526A1 (en) 2008-09-25
EP4245299A3 (en) 2023-12-13
EP2508188B1 (en) 2023-05-10
BRPI0809233B1 (en) 2017-09-26
MX2020009329A (en) 2022-04-26
KR20090123964A (en) 2009-12-02
EA200901277A1 (en) 2010-02-26
EA020288B1 (en) 2014-10-30
KR101454051B1 (en) 2014-10-27
JP5475636B2 (en) 2014-04-16
SI2508188T1 (en) 2023-09-29
US8221786B2 (en) 2012-07-17
KR20140069365A (en) 2014-06-09
KR101532188B1 (en) 2015-06-29
EP2139494A1 (en) 2010-01-06
CY1123143T1 (en) 2020-11-25
RS60258B1 (en) 2020-06-30
HUS2000036I1 (en) 2020-10-28
CA2929811A1 (en) 2008-09-25
US8361972B2 (en) 2013-01-29
HRP20230691T1 (en) 2023-10-13
KR101772776B1 (en) 2017-08-29
CL2008000823A1 (en) 2008-11-14
FR20C1042I1 (en) 2020-10-16
HUE048897T2 (en) 2020-08-28
CY2020022I1 (en) 2020-11-25
PL2139494T3 (en) 2020-09-21
US20130129819A1 (en) 2013-05-23
CY2020022I2 (en) 2020-11-25
US20140243262A1 (en) 2014-08-28
DK2139494T3 (en) 2020-05-25
JP2014111636A (en) 2014-06-19
CN101686988B (en) 2013-12-11
LT2139494T (en) 2020-05-25
ES2791682T3 (en) 2020-11-05
MX2009010155A (en) 2009-10-12
HK1176004A1 (en) 2013-07-19
LTPA2020522I1 (en) 2020-07-27
PT2508188T (en) 2023-07-24
CN102743340A (en) 2012-10-24
US20080234366A1 (en) 2008-09-25
EP2508188A1 (en) 2012-10-10
WO2008116179A1 (en) 2008-09-25
BR122017015098B8 (en) 2021-07-27
HRP20200753T1 (en) 2020-07-24
EP4245299A2 (en) 2023-09-20
CA2681526C (en) 2016-07-19
DK2508188T3 (en) 2023-07-31
AU2008228714A1 (en) 2008-09-25
AR065809A1 (en) 2009-07-01
CN102743340B (en) 2015-07-15
KR20160013276A (en) 2016-02-03
US7851502B2 (en) 2010-12-14
CN101686988A (en) 2010-03-31

Similar Documents

Publication Publication Date Title
AU2008228714B2 (en) Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
AU2010319377B2 (en) Immediate release tablet formulations
AU2014201239B2 (en) Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
AU2014218386A1 (en) Immediate release tablet formulations

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE CO-INVENTOR FROM WU, YONGEMEI TO WU, YONGMEI

FGA Letters patent sealed or granted (standard patent)
PC1 Assignment before grant (sect. 113)

Owner name: ASTRAZENECA AB

Free format text: FORMER APPLICANT(S): BRISTOL-MYERS SQUIBB COMPANY